6-Mercaptopurine and 6-Thioguanine: a fresh look on vintage anticancer drugs by Schouten, T.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113225
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
SH 
I 
N ^ С ^ 
i il o u 
υπ 
H 
6-MERCAPTOPUR NE AND 6-TH OGUAN NE: 
SH 
1 II CH 
H 2 N / C ^ C , V 
H 
A FRESH LOOK 
ON V NTAGE ANT CANCER DRUGS 
i 
i : * 
TEUN S J. SCHOUTEN f 

6-MERCAPTOPURINE AND 6-THIOGUANINE: 
A FRESH LOOK ON VINTAGE ANTICANCER DRUGS 
proefschrift 
ter verkrijging van de graad van 
doctor in de geneeskunde 
aan de Katholieke Universiteit te Nijmegen 
op gezag van de rector magnificus 
Prof. Dr. J.H.G.I. Giesbers 
volgens besluit van het college van dekanen 
in het openbaar te verdedigen 
op donderdag 23 mei 1985 
des namiddags te 4.00 uur 
door 
TEUN IS JAN SCHOUTEN 
geboren te Meerkerk (Z.H.) 
1985 
druk: Stichting Studentenpers Nijmegen 
Promotor : Prof. Dr. E.D.A.M. Schretlen 
Co-referenten : Dr. R.A. De Abreu 
Dr. G.A.M, de Vaan 
The investigations described in this thesis were performed in the Centre 
for Pediatric Oncology S.E. Netherlands, Department of Paediatrics 
(Head: Prof.Dr.E.D.A.M. Schretlen, at present Prof.Dr.G.B.A. Stoelinga), 
University Hospital "Sint Radboud", Nijmegen, the Netherlands. 
The studies were supported by a grant (SNUKC 81-2) from the Queen 
Wilhelmina Foundation, the Netherlands Organization against Cancer 
(KWF/NOK). 
Printing-expenses were partly subsidized by the "Ank van Vlissingen 
Fonds". 
11 uvn uaclm, рчхуто к т Ь . 
11 Lim uacU/t САІШ: nmatXAt АЖлгіа biicl 
íu¿ ι\κγοΙ £/я шед^ оЬ тсюл/ cLooa, 
дзпі е ^ peJv. 
l/) сельпо:,,Цая cynaun аала miyrt жор, 
сшшлп аала ' 
jDxi iota ел\ cUyrílcW op. 
Ta, τ η ^ η vxxoW p^rçouanX 
Г La ctC cU| Acu>wrv лгоор ιΑ dea лги ел, oaK noa 
imk u)cvrv леедА- " 
iLa LO Avo, жХаая/ 
{Mb oumùjuvi. 

CONTENTS 
abbreviations 
CHAPTER I. 
6-MERCAPTOPURINE AND 6-THIOGUANINE: BACKGROUND OF THE STUDIES 
- introduction 
- metabolism 
- methods to measure cytotoxic effects of drugs in vitro 
- starting point and evolution of the studies on 6-mercapto-
purine and 6-thioguanine 
- references 
CHAPTER II. 23 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF PLASMA 
6-MERCAPTOPURINE IN CLINICALLY RELEVANT CONCENTRATIONS 
- introduction 
- experimental 
- results and discussion 
- conclusions 
- references 
CHAPTER III. 33 
SENSITIVE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION 
OF 6-MERCAPTOPURINE, 6-THIOGUANINE, 6-MERCAPTOPURINE RIBOSIDE AND 
6-THI0GUAN0SINE IN BIOLOGICAL FLUIDS 
- introduction 
- experimental 
- results and discussion 
- references 
CHAPTER IV. 41 
6-MERCAPTOPURINE: PLASMA AND CSF CONCENTRATIONS DURING MAINTENANCE 
TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA 
- introduction 
- materials and methods 
- results 
- discussion 
- references 
CHAPTER V. 49 
6-MERCAPTOPURINE: ORAL ADMINISTRATION AND I.V. BOLUS INJECTIONS 
IN DOGS 
- abstract 
- introduction 
- materials and methods 
- results 
- discussion 
- references 
CHAPTER VI. 63 
6-MERCAPTOPURINE: TOTAL BODY AUTORADIOGRAMS AND PLASMA CONCENTRA-
TION-TIME CURVES OF 6MP AND METABOLITES FROM MARMOSET MONKEYS 
- abstract 
- introduction 
- materials and methods 
- results 
- discussion 
- references 
CHAPTER VII. 75 
6-THIOGUANINE: HIGH-DOSE TWO HOURS INFUSIONS IN GOATS 
- summary 
- introduction 
- materials and methods 
- results 
- discussion 
- references 
CHAPTER VIII. 87 
6-MERCAPTOPURINE: HIGH-DOSE 24 HOURS INFUSIONS IN GOATS 
- abstract 
- introduction 
- materials and methods 
- results 
- discussion 
- references 
- addendum 
6 
CHAPTER IX. 107 
6-MERCAPTOPURINE AND 6-THIOGUANINE: SURVEY AND SUMMARY 
- 6MP and 6TG as antileukaemic agents and the aim of our 
investigations 
- 6MP and 6TG: survey of our studies 
- development of sensitive and specific methods to determine 
6MP, 6TG, 6MPR and 6TGR 
- explorative pharmacokinetic studies in ALL patients and dogs 
- infusions of 6MP and 6TG in monkeys and goats 
- 6MP: evaluation of recent pharmacological and pharmacokinetic 
studies from the literature 
- 6TG: evaluation of recent pharmacological and pharmacokinetic 
studies from the literature 
- 6MP and 6TG: a fresh look on their application 
- conclusion 
SAMENVATTING 127 
WOORDEN VAN DANK 131 
CURRICULUM VITAE 133 
LIST OF PUBLICATIONS 134 
7 
ABBREVIATIONS 
acute lymphoblastic leukaemia 
acute myeloid leukaemia 
area under (the concentration-time) curve 
central nervous system 
cerebrospinal fluid 
Dutch Childhood Leukaemia Study Group 
dithiothreïtol 
hypoxanthlne guanine phosphoribosyl transferase 
high-performance liquid chromatography 
Intravenous 
6-mercaptoguanine riboside (=6-thioguanine riboside) 
6-mercaptopurine 
6-mercaptopurine riboside 
methotrexate 
phosphoribosylpyrophosphate 
Stichting Nederlandse Werkgroep Leukemie bij Kinderen 
(Dutch Childhood Leukaemia Study Group) 
trichloroacetic acid 
6-thioguanine 
6-thioguanine riboside (=6-thioguanosine) 
6-thioxanthine 
6-thio-uric acid 
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CHAPTER I 
6-MERCAPTOPURINE AND 6-THIOGUANINE: BACKGROUND OF THE STUDIES 
INTRODUCTION 
6-Mercaptopurine (6MP) and 6-thioguanine (6TG) were synthesized for use 
as analogs of natural purines (1, 2, 3). The hypothesis was that analogs 
might be metabolized initially in the same way as there natural counter-
parts, but yet could derange the metabolism of the malignant cells, ul-
timately leading to cell death. Such analogs are called antimetabolites. 
6MP is used in the treatment of acute leukaemia and the first results in 
patients were reported in 1953 by Burchenal et al (4). In the sixties 
the role of 6MP changed from inducing haematological remission to main-
taining such a remission (5, 6). Nowadays 6MP is administered in the 
maintenance treatment of acute lymphoblastic leukaemia (ALL) essentially 
in the same way and in the same dose as it was used 30 years ago. This 
means administration ot low doses by the oral route (5, 6). 6MP is com-
bined with methotrexate (MTX), the latter drug being given once or twice 
a week (5, 6). The combination of 6MP and MTX has been used on empirical 
grounds for nearly 20 years, but recently arguments for a synergistic 
biochemical interaction have been raised (7, 8). Such a biochemical 
synergistic interaction can be demonstrated in vitro only at much higher 
concentrations than those obtainable in vivo after administration of the 
drugs in customary doses and schedules. Further investigations in vitro, 
and translation of the results into in vivo relevant dosages and schedu-
les, are certainly warranted (7, 8). 
The other thlopurine we studied, 6TG, is mainly used in the treatment of 
acute myeloid leukaemia (AML). The customary use of 6TG, Instead of 6MP, 
in the treatment of AML is based more on convention than on a deliberate 
choice (3). 6TG too is administered usually by the oral route. 
METABOLISM 
6MP and 6TG are analogs of hypoxanthine and guanine, respectively (fig. 
1). Both drugs differ from their natural analogs by having a SH group 
instead of an OH group attached at the 6 position of the purine ring. 
Both drugs can be metabolized initially in the same way as their natu-
ral counterparts, but ultimately cause a derangement of the metabolism 
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Fig. 1. Structural formulas of 6-mercaptopurine and 6-thioguanine, with 
their natural counterparts hypoxanthine and guanine, respectively. 
of the cell, eventually leading to the death of this cell. Before 
discussing the various mechanisms of cell kill we will discuss briefly 
the normal purine metabolism. 
The natural purines can be synthesized from simple precursors, starting 
from PRPP, by a ten step route of metabolism called the de novo synthe­
sis (fig.2) (9). The first purine resulting from this pathway is inosine 
monophosphate (IMP) which can be converted into adenine and guanine 
nucleotides by the purine interconversion enzymes (fig.2). 
The first step in the purine de novo synthesis is catalyzed by the en­
zyme phosphoribosylpyrophosphate glutamyl amidotransferase and this rate 
limiting enzyme in the purine de novo synthesis is susceptible to feed­
back inhibition by IMP and IMP analogs. This is relevant for the bioche­
mical effects, which can be produced by thiopurine metabolites. 
The de novo synthesis is a multi-step energy requiring pathway, and the 
economy of the cells is served by the existence of the so-called salvage 
pathway. In this pathway the natural purine bases are "salvaged" from 
degradation to xanthine and uric acid by conversion to their respective 
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ABBREVIATIONS USED IN FIG. 2 STARTING FROM TOP OF THE SCHEME 
R-5-P ribose-5-phosphate 
PRPP ar-D-5-phosphoribosyl pyrophosphate 
PRA 5-phospho-ß-D-ribosylamine 
GAR 5'-phosphoribosylglycinamide 
FGAR 5'-phosphoribosy1-N-formyIglycineamine 
FGAM 5'-phosphoribosy1-N-formylglycineamidine 
AIR 5 ' -phosphoribosyl-5-aminoiinidazole 
CAIR 5'-phosphoribosyl-4-carboxy-5-aminoimidazole 
SAICAR 5'-phosphoribosyl-4-(N-succinocarboxamide-)5-aminoimi-
dazole 
AICAR 5'-phosphoribosyl-5-amino-4-imidazole carboxamide 
FAICAR 5,-phosphoribosyl-5-formamido-4-imidazole carboxamide 
IMP inosine-5'-monophosphate 
sAMP adenylosuccinate 
XMP xanthosine-5'-monophosphate 
(d)AMP (deoxy)adenosine-5'-monophosphate 
(d)ADP (deoxy)adenosIne-5'-diphosphate 
(d)ATP (deoxy^denosine-S* -triphosphate 
(d)GMP (deoxy)guanosine-5'-monophosphate 
(d)GDP (deoxy)guanosine-5'-diphosphate 
(d)GTP (deoxy)guanosJ ne-5'-triphosphate 
NUMBER 
1 
2 
3 
4 
5 
б 
7 
8 
9 
10 
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12 
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ENZYME 
phosphoribosylpyrophosphate aminotransferase 
IMP-dehydrogenase 
adenylosuccinate synthetase 
adenylosuccinase 
hypoxanthlne guanine phosphorlbosyl transferase (HGPRT) 
AMP-deaminas e 
5'-nucleotidase 
adenosine kinase 
adenosine deaminase 
adenine phosphorlbosyl transferase 
purine nucleoside Phosphorylase 
xanthine oxidase 
guanase 
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PURINE METABOLISM 
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Fig. 2. The vertical chain of reactions starting with PRPP and termina-
ting in IMP represents the purine de novo synthesis. The reactions indi-
cated horizontally from IMP to GMP and AMP, are the interconversions. 
The reactions from guanine, hypoxanthine and adenine back to the cor-
responding ribonucleotide monophosphates are called the salvage pathway. 
For abbreviations and meaning of the numbers see opposite page. 
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monophosphates (fig.2). Hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) catalyzes the ribophosphorylation of guanine and hypoxanthine 
into GMP and IMP, respectively. Adenine phosphoribosyltransferase is in­
volved in the ribophosphorylation of adenine to AMP. Phosphoribosylpyro-
phosphate (PRPP) functions as a co-substrate for these "salvage" reac­
tions. 
Both 6MP and 6TG can substitute in the purine salvage pathway for their 
natural analogs hypoxanthine and guanine (fig.3), for review see Pater-
son and Tidd (1975) and LePage (1977) (1, 2). The salvage enzyme hypo­
xanthine guanine phosphoribosyl transferase and the cosubstrate PRPP are 
of course of critical importance for the activation of the thiopurines 
to there monophosphates. 6MP is converted to 6-thio-IMP and 6TG to 
6-thio-GMP. 6-Thio-IMP can be methylated to 6-methyl-thio-TMP or inter-
METABOLISM of 6MP and 6TG 
6-thio-dGDP —•e-thio-dGTP > D N A 
6-thio-GDP —•6-thio-GTP — — • R N A 
\ 6-thio-XMP 
e-methyl-tho-GMP'e-e-thio-GMP • 6-thio-IMP — + • 6-methyl-thio-IMP 
7i \ / I7 4 
6TGR Л к . 6MPR 6-methyl-MPR 
6-methyl-TG Л 6TG 6MP^^£6-methy l -MP 
e-methyl-TX 6TX 6-methyl-TX 
12І |12 |12 
6-methyl-TU 6TU 6-methyl-TU 
Fig. 3. The metabolic scheme is analogous to figure 2, with 6TG and 6MP 
instead of the natural counterparts, guanine and hypoxanthine, respec­
tively. (Abbreviations: 6(-methyl-)TU:6-(methyl-)thio-uric acid, 6(-me-
thyl-)TX:6-(methyl-)thioxanthine, 6(-methyl-)MP(R):6-(methyl-)mercapto-
purine (riboside), 6(-methyl-)TG(R): 6-(methyl-)thioguanine (riboside). 
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converted to 6-thio-GMP. 6-thio-GMP can be methylated to 6-methyl-thio-
GMP or further metabolized to 6-thio-GDP and 6-thio-GTP and eventually 
be incorporated into RNA. At the level of 6-thio-GDP the action of a re-
ductase can lead to formation of 6-thio-dGDP and a kinase then produces 
6-thio-dGTP, which can be incorporated into DNA. 
As mentioned before, IMP is capable of feed-back inhibition of the pu-
rine de novo synthesis, and one may expect the same inhibition from 6-
thio-IMP and 6-thio-GMP. This is indeed the case, especially 6-methyl-
thio-IMP exerts a strong feed-back inhibition of the purine de novo syn-
thesis. For 6-methyl-thio-GMP this inhibition is not observed (1, 10). 
As a result of the inhibition of the first step in the de novo synthe-
sis, PRPP can accumulate and this leads to increased synthesis of 6-
thio-IMP by the salvage pathway: the so-called "self enhancement". The 
strong biochemical perturbations in the purine metabolism caused by 
6-methyl-thio-IMP and similar metabolites result in growth inhibition, 
but not in irreversible damage leading to cell death (1, 2). So the ul-
timate site of cytotoxic effect of 6MP and 6TG is most probably their 
incorporation into DNA (as 6-thio-dGTP) and, to a lesser extent, into 
RNA (as 6-thio-GTP) (1, 2, 11, 12, 13, 14, 15, 16). 
As the incorporation into DNA is the main site of cytotoxicity for 6MP 
and 6TG, it follows that 6MP and 6TG can only be effective when cells 
pass through the S-phase of the cell cycle. It is especially in this 
phase that precursors of DNA and DNA itself are assembled. The specifi-
city of 6MP and 6TG for those phases of the cell cycle in which nucleo-
tides and DNA are synthesized for DNA duplication, has been demonstrated 
repeatedly (12, 13, 14). 
The antimetabolites 6MP and 6TG, if used in the appropriate concentra-
tion in vitro or dose and schedule in vivo, will only exert a cytostatic 
effect on tumour cells which are actively proliferating. Moreover, as 
the individual cells from a cell population are randomly distributed in 
the various phases of the cell cycle, 6MP and 6TG must be present at 
least for as long as the duration of the cell cycle for those particular 
cells. 
The catabolism of 6MP and 6TG Is very similar to that of hypoxanthine 
and guanine (fig.2 and 3) (1, 2, 9). So 6MP is susceptible to xanthine 
oxidase. This enzyme is present in large amounts in intestinal epithe-
lial cells and in liver cells. Xanthine oxidase oxidizes 6MP in two 
15 
Steps to 6-thio-uric acid (6TU). 6TU and the preceding intermediate 
metabolite 6-thioxanthine (6TX) are excreted in urine (1). 
6TG is first deaminated by guanase, an enzyme which is not that abun-
dant in the human body as is xanthine oxidase. Guanase catalyzes the 
deamination of 6TG to 6-thioxanthine, and 6-thioxanthine is further 
degraded to 6-thio-uric acid by xanthine oxidase (1). 
METHODS TO MEASURE CYTOTOXIC EFFECTS OF DRUGS IN VITRO 
In considering the methods by which a cytostatic effect is measured, one 
should realize very well that cure of malignant disease by chemotherapy 
can only be attained if all malignant cells, including the last one, are 
destroyed (17, 18). The concept of log kill has been especially helpful 
in our understanding of the effects of cytotoxic drugs (17). So, methods 
which actually can measure cell kill in several logs are likely the best 
ones to attain a correlation with the cytotoxicity relevant in vivo. 
Clonogenlc assays of malignant cells seem best suited to transpose in 
vitro data to in vivo studies (19, 20, 21, 22, 23). However, these clo-
nogenlc assays are not without problems, especially for solid tumour 
samples obtained from humans (24, 25). 
In leukaemia it is somewhat easier to obtain samples for clonogenlc as-
says (26, 27). Some authors have successfully used those assays in che-
mosensitivity testing (28, 29). They draw attention to the factor of 
duration of drug exposure, especially for S-phase specific drugs. Both 
groups found better predictive values by continuous exposure to cytosine 
arabinoside than by 1 hour pulse exposure (28, 29). Park and coworkers 
conclude from their data that on the one hand it may be important to si-
mulate the in vivo situation for getting better predictive results with 
in vitro tests, but their data indicate on the other hand the possibili-
ty that this in vitro leukaemia clonogenlc assay might be used as a 
guide to determine the most efficacious schedule of clinical drug admi-
nistration (28). 
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STARTING POINT AND EVOLUTION OF THE STUDIES ON 6-MERCAPTOPURINE AND 
6-THIOGUANINE 
6MP is one of the two drugs which are extensively used in the mainte-
nance treatment of childhood ALL (5, 6). We planned our project on 6MP, 
because only a few studies on the pharmacokinetics and metabolism of 6MP 
in this clinical situation were available (1, 2 ,3). The know-how in the 
field of purine metabolism existing in our institution formed a basis to 
start our investigations on the purine analogs, 6MP and 6TG. We perfor-
med our study on the use of 6MP in ALL patients receiving maintenance 
treatment according to the operative protocol of the "Stichting Neder-
landse Werkgroep Leukemie bij Kinderen" (Dutch Childhood Leukaemia Study 
Group). 
As the first objective we were obliged to develop a reliable method for 
the determination of 6MP, as there was no standard method to quantitate 
6MP in biological fluids. Such a method has to be specific and sensiti-
ve, especially because the low dose of 6MP applied in the maintenance 
treatment of ALL results in very low plasma concentrations. We solved 
this problem by using high-performance liquid chromatography (HPLC) 
(Chapter II). The presence of a protective agent for 6MP, from the mo-
ment the sample of biological fluid was taken and throughout the total 
analytical procedure, was a major step. By using a relatively large in-
jection volume the sensitivity of the method became adequate. The method 
described in Chapter II was applied to study plasma and CSF concentra-
tions of 6MP in patients and in animals (Chapters IV, V, VI).Later the 
method of analysis was refined to include the quantitation of 6MP ribo-
side (Chapter III). Moreover the method was changed in such a way that 
6TG and 6TG riboside could be quantitated by the same analytical proce-
dure. This has practical advantages when performing investigations both 
on 6MP and 6TG as we did in the second part of the study. 
The orientating study on patients receiving 6MP as part of their mainte-
nance treatment raised several questions, which should be elucidated in 
further studies. In our study a very important finding was the good pe-
netration of 6MP into CSF in patients, with a ratio of CSF to simulta-
neous plasma concentrations of about 0.40 (Chapter IV). However the con-
centrations of 6MP measured were much lower than the concentrations 
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which exert a cytotoxic effect in in vitro studies on mouse leukaemia 
and lymphoma cells (11, 30, 31). 
The very low plasma concentrations observed in patients led to further 
exploration in an experimental animal model (Chapter V). With regard to 
dose and schedule of 6MP administration we conformed us to the operative 
protocol of maintenance therapy. This means we used a dosage of about 2 
mg/kg/day in dogs and administered this dose by the oral route as a 
rule. To study the plasma concentration-time curves of 6MP adequately, 
we resorted to i.v. bolus injections, still at the customary dose. 
Although the concentrations which we measured after i.v. bolus injec-
tions were much higher than after oral administration, these concentra-
tions of 6MP were still relatively low in comparison with the concentra-
tions used in in vitro cytotoxicity studies. Moreover, the concentra-
tions of 6MP after i.v. bolus injections declined to very low levels 
after just a few hours. In vitro studies had shown that not only concen-
trations of 6MP in the order of 100-200 vM were necessary for a maximal 
effect, but also that the cells should be exposed to these concentra-
tions for a long time. In biological terms the period of exposure should 
be in the order of 1-2 median cell cycle lengths (11). 
The results from our studies in patients and dogs are pointing to chan-
ging the usual dosages, routes and schedules of administration of 6MP. 
We also included 6TG in our further search for a reliable application of 
purine antagonists. Both substances are closely related structurally and 
the mechanism of cytotoxicity is very similar. 6TG might have some ad-
vantage over 6MP as the biochemical pathway leading to incorporation in-
to DNA is more straightforward for 6TG than for 6MP. In vitro studies 
using mouse lymphoma cells had demonstrated that 6TG exerts its maximal 
cell kill at lower concentrations and that the maximal cell killing ef-
fect is somewhat greater for 6TG (11). 
During the last years the customary dose and way of administration were 
already in discussion in the literature (32, 33). Studies were reported 
on the low bioavailability of 6MP after oral administration. For this 
reason parenteral administration of 6MP and 6TG during prolonged periods 
of time seemed worthwhile. A report by Frei and Cancellos on dose as a 
critical factor in cancer chemotherapy (18) and the high concentrations 
used in in vitro studies (11) made us to consider the effect of high do-
ses of 6MP and 6TG. In the report by Frei and Canellos the concept of 
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"maintenance" chemotherapy is rejected in curatively intended chemothe-
rapy. The original goal of maintenance treatment was not directed at 
cure, but rather at prolonging the time to relapse. The authors state 
that there is no clear evidence from any study that maintenance treat-
ment will increase the cure rate. The philosophy of maintenance treat-
ment is not based on good therapeutic principles derived from fundamen-
tal biologic studies and is not in accord with the results of more re-
cent and sophisticated clinical trials (18). 
In Chapters VI, VII and VIII we report on studies in monkeys (6MP) and 
goats (6TG and 6MP). The drugs, 6MP and 6TG, were administered by infu-
sion. In our study in monkeys, using radiolabeled 6MP, an infusion pe-
riod of one and four hours was used (Chapter VI). A relatively high dose 
rate of 6MP was given, i.e. 5 mg/kg/hour. In Chapter VII the results of 
two hours infusions of 6TG into goats, at a dose rate of 2 mg/kg/hour, 
are reported. In Chapter VIII really prolonged, i.e. 24 hours, infusions 
of 6MP are applied at different dose rates. The confirmation of the 
finding of good penetration of 6MP and also 6TG into CSF in these stu-
dies in goats is worth to be mentioned beforehand. 
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Since 1953 the drug 6-mercaptopurine (6MP) has been used extensively 
in the treatment of leukemia [1] . This purine analogue was first applied to 
induce and maintain remission of the leukemic process. During the last decade 
6MP has been used for maintaining remissions induced with other agents [2] . 
The first pharmacokinetic studies in man were reported by Hamilton and 
Elion [3]. They used radioactive 6MP (3SS) to study plasma and urine levels 
of the drug in two patients with leukemia. Column and paper chromatography 
were used to separate urinary metabolites. The intravenous route of admin-
istration has mostly been used in experimental studies. In clinical practice, 
however, oral therapy is the rule [2, 4] . 
Later pharmacokinetic studies are scant. The main reason for this might 
be the lack of specific and sensitive methods for determination of 6MP. A 
colorimetrie determination of 6MP in plasma has been described [5] . Prob-
lems of specificity, especially interference of natural purine metabolites, were 
circumvented by using the patients' own pre-treatment plasma for the refer-
ence determinations. The lower limit of detectability was in the range of 
0.2—0.5 Mg/ml. For duplicate determinations about 20 ml blood were neces-
sary and about 50 ml for producing reference plasma samples. Finkel [6] 
described a fluorimetrie method with approximately the same sensitivity 
0378-4347 /82/000O-0000/$02.75 © 1982 Elsevier Scientific Publishing Company 
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(± 1.0 Mg/ml), which required less blood per determination. 
In recent years, several high-performance liquid chromatographic (HPLC) 
methods for the determination of 6MP in blood have been described [7—9]. 
Although these HPLC methods are relatively easy to perform, the sensitivity 
is still not optimal (0.2 ug/ml) [7] . Two systems, mainly designed for the 
determination of azathioprine, require a time-consuming extraction method 
with 12% and 50% recovery, respectively [8, 9 ] . The lower limit of detect-
ability is in the range of 5 ng/ml. Only small amounts of serum or plasma 
are necessary per determination (0.5—1 ml). 
In the present paper we describe an HPLC method designed for the identifi­
cation and quantitation of 6MP in plasma. The lower detection limit is ap­
proximately 3 ng/ml. An application of the method is illustrated by means 
of pharmacokinetic studies, using a common clinical dose level [ 2 ] . 
EXPERIMENTAL 
Chemicals 
6MP, 6-mercaptopurine riboside (6MPR), and 6-mercaptoguanme ribosibe 
(6MGR) were purchased from Sigma (St. Louis, MO, U.S.A.); dithiothreitol 
(DTT) was from Boehringer (Mannheim, G.F.R.); all other chemicals were from 
E. Merck (Darmstadt, G.F.R.), all of the highest analytical grade. 
Sample preparation 
Venous blood samples of 2 ml were collected in tubes containing heparin 
and also 120 tig of DTT to prevent oxidation of 6MP. After mixing, the blood 
sample was centrifuged (5 min, 2000 g) and the plasma was pipetted into 
micro test-tubes (type 3810, Eppendorf, Hamburg, G.F.R.), and kept on ice 
for 5 min. Ice-cold 50% (w/v) trichloroacetic acid (TCA) was added in an 
amount of one-tenth of the plasma volume. After mixing vigorously, the 
suspension was kept on ice for another 10 min. Precipitated protein was 
removed by centrifugation (10 min, 2000 g) and the supernatant (TCA ex­
tract) was adjusted to a pH of between 6 and 7 with 4.0 M potassium hy­
droxide. 
Sfocft solutions 
Stock solutions of 6MP were prepared from which standard solutions were 
obtained by dilution. Standard solutions were used for calibration and stan­
dardisation of the HPLC method. 6MP (10 mg) was dissolved in a solution 
of 0.025 M potassium diphosphate containing 60 mg/1 DTT, and adjusted 
to a pH of about 10.0 with 4.0 M potassium hydroxide. 
After 6MP had completely been dissolved, the pH of the solution was 
adjusted to pH 6.6 with phosphoric acid and diluted to a concentration of 
1 mg/ml. The stock solution was kept at a temperature of 4° С and was stable 
for at least two weeks. 
6MP solutions for intravenous injection 
Solutions for intravenous injection were freshly prepared; 60 mg of 6MP 
were dissolved in 0.25 ml of a 5.0% solution of sodium hydroxide. When 
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diluted with sterile physiological saline to a 6MP concentration of 10 mg/ml, 
the pH of the solution was about 10.0. The solution was used shortly after 
preparation. For the animal experiments 5 ml of the solution were injected, 
while passing through a sterile Millipore type Millex-GS membrane filter 
(pore size 0.22 μτη). 
Instrumen ta tion 
The experiments were performed on a Spectra Physics SP-8000 high-per­
formance liquid Chromatograph equipped with an auto-injector with Valco 
valve, an automated data system with integrator and a two-channel printer-
plotter. The volume of the sample loop was 460 μΐ. Column effluents were 
monitored with two fixed SP 8210 UV detectors (Spectra Physics) set at 
wavelengths of 312 nm and 280 nm, respectively. Both detectors had an 
8-μ1 flow cell. 
HPLC procedure 
Chromatography was carried out at a constant flow-rate of 1.5 ml/min 
on two Spherisorb 10-ODS (particle size 10 μτη) reversed-phase columns 
(250 mm X 4.6 mm I.D.) in series. Α 460-μ1 sample of neutralized TCA ex­
tract was injected on the columns and was eluted with 0.050 M potassium 
phosphate buffer (pH 6.35). Before use the phosphate buffer was filtered 
through a Millipore type HA membrane filter (pore size 0.45 μιη) and during 
elution the buffer was degassed by continuous helium purging. The maximum 
run-time was 30 min. Integrated peak areas at 312 nm were used for calculat­
ing the concentrations. 
RESULTS AND DISCUSSION 
Stability 
At low pH 6MP is poorly soluble. The solubility is much better at basic 
pH but then 6MP is easily oxidized. Therefore, we found it necessary to sta­
bilize stock solutions and blood samples with DTT. The addition of DTT 
remarkably increased the stability, and the average recovery from standards 
added to plasma increased from 20% (without DTT) to 94% (with 60 μg of 
DTT per ml of plasma). 
Chromatographic conditions 
The scan patterns of human plasma spiked with 6-thiouric acid, 6-thio-
xanthine, 6MP, 6MPR and 6MGR (Fig. la) show a good separation. The 
plasma samples are free from compounds interfering with the deiection of 
these components under the chromatographic conditions used (Fig. lb). 
Calibration and quantification 
Calibration curves were made using standard solutions of increasing con­
centration. The peak areas were calculated by automatic integration at 312 
nm. The linearity is good; little, if any, difference exists between determina­
tions carried out in plasma and those carried out in aqueous solution. The 
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15 minutes 
Fig. 1. Elution profiles of the separation of 6MP, 6MPR and 6MGR on Spherisorb-ODS col-
umns (for separation conditions, see Experimental), (a) Chromatogram of human plasma 
sample with added 6-thiouric acid (6TU), 6-thioxanthine (6TX), 6MP, 6MPR and 6MGR. 
(b) Chromatogram of human plasma sample without addition of mercaptopurines. 
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Fig. 2. HPLC of 6MP in plasma of a 28-kg Labrador dog. (a) Plasma sample collected before 6MP administration (b) Plasma sample collected 
10 min after intravenous injection of 50 mg of 6MP. (c) Plasma sample collected 5 h after intravenous injection of 50 mg of 6MP. 
recovery of 6MP added to plasma is 94 ± 5%. The relationship between 6MP 
plasma concentration in the range 3—1800 ng/ml and peak area is: concen­
tration = (4.59· 10"4 int. area + 3.30) ng/ml. The correlation coefficient is 
0.9994. In a low concentration range (3—100 ng/ml) the correlation coef­
ficient between concentration and peak area is 0.9970. In this concentra­
tion range the relationship between 6MP concentrations and peak area is: 
concentration = (4.63· 10"4 int. area + 2.6) ng/ml. The lower detection limit 
is approximately 3 ng/ml using a 460-μ1 loop. 
Analysis of plasma levels of 6MP after an intravenous bolus injection in a 
Labrador dog 
Typical scans of TCA extracts before injection (a), and 10 min (b) and 5 h 
(с) after injection are shown in Fig. 2. The profiles presented in the figure are 
representative of time-dependent decline of the 6MP levels. By means of 
computer· analysis, the concentration—time curve can be fitted in a model 
with two half-lives for 6MP. The semi-logarithmic plot in Fig. 3 expresses 
the relationship between the 6MP levels in plasma and the time after intra­
venous injection. The calculated half-life times are 21 min and 130 min, with 
correlation coefficients of 0.985 and 0.968, respectively. 
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Fig. 3. Plasma levels of 6MP as a function of time after intravenous injection of a 28-kg 
Labrador dog with 50 mg of 6MP. 
CONCLUSIONS 
The sensitivity of the method presented here is more than sufficient to 
follow the pharmacokinetic behaviour of 6MP in plasma for several hours 
after a clinical dose. Although HPLC methods are commonly used [7—12], 
the extraction methods do not seem optimal since low recoveries are reported 
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in the ng/ml range [8, 9 ] . The extraction procedure is very critical due to 
the lability of the mercapto (SH) group of 6MP. The addition of DTT is im­
portant since, as a reducing agent, it stabilizes the SH group of 6MP, and it 
increases the recovery from 20 to 94%. Another important factor is to keep 
the extraction procedure as short and as simple as possible. It is advisable to 
perform the extraction in the cold in order to reduce the risk of oxidation 
at room temperature. Recently Ding and Benet [8] have advised the use of 
dithioerythritol. This compound has a stabilizing effect comparable to that 
of DTT, so it might have contributed to increasing the recovery. However, 
a recovery of only 12% was obtained [8] . With our method it should be 
possible to measure 6MP in plasma from leukemic patients and to perform 
pharmacokinetic studies of 6MP during maintenance treatment. Further 
studies to define the pharmacokinetic behaviour of 6MP in Labrador dogs 
and also in patients with acute leukemia using the method described in this 
paper are at present underway in our laboratory. 
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For parallel studies on 6-mercaptopurine (6MP) and 6-thioguanme (6TG), a 
system is desirable to measure both drugs, as well as their metabolites 
6-mercaptopurine riboside (6 MPR) and 6-thioguanosine (6TGR). The method 
we described previously [1] is not suitable for measuring 6TG and 6TGR, 
because 6TG was not separated from 6MP, and because the peak of 6TGR was 
very broad. Other methods for the determination of 6-thiopurines have been 
reported, but are less suitable for our purposes either becavise the lower limit of 
detectability is not low enough [2—6] or because extraction of the samples is 
too time-consuming [7—10]. In the present paper we describe a high-perfor­
mance liquid chromatographic (HPLC) method for the identification and 
quantitation of 6MP, 6TG, 6MPR and 6TGR in plasma, cerebrospinal fluid 
(CSF) and urine. 
EXPERIMENTAL 
Chemicals 
6MP and 6TG were products of Fluka (Hicol, Rotterdam, The Netherlands); 
6MPR and 6TGR were from Sigma (St. Louis, MO, U.S.A.); xanthine oxidase 
and dithiothreitol (DTT) were from Boehringer (Mannheim, F.R.G.); all other 
chemicals were from E. Merck (Darmstadt, F.R.G.); helium was from Hoekloos 
(Amsterdam, The Netherlands). Water used for all solutions was purified 
through a Milli-Q-System (Millipore, Bedford, MA, U.S.A.). 
0378-4347/84/$03.00 © 1984 Elsevier Science Publishers B.V. 
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HPLC procedure 
Experiments were performed on a Spectra Physics HPLC SP 8000B (Spectra 
Physics, Santa Clara, CA, U.S.A.), connected to an automatic sampler MSI 660 
(Kontron, Electrolab, London, U.K.). Column effluents were monitored with a 
fixed-wavelength ultraviolet (UV) detector SP 8210 (Spectra Physics) at 312 
nm and a variable-wavelength UV/VIS detector Model 770 (Spectra Physics) 
set at 342 nm. Detector signals were plotted on a two-channel printer—plotter 
of the HPLC apparatus. Peak areas were correlated to concentrations, as will 
be discussed later. 
The columns were packed in our laboratory with Nucleosil 10 Cig, particle 
size 10 μπι (Chrompack, Middelburg, The Netherlands). During packing a 
reservoir was connected directly on top of the column tube, and a slurry of 
Nucleosil (3 g of Nucleosil in 10 ml of methanol) was pumped into the column 
(250 mm X 4.6 mm I.D.) by means of the HPLC pump. Methanol 50% (v/v) 
was used as eluent and the pressure was kept at about 21 MPa by controlling 
the flow-rate. 
312 nm ^рГ" 
312nm 
rïf Ίψ 
plasma CSF 
.Ju 
τ 
I 1 1 L 1— 
Ù 5 Ю 15 min 
Fig. 1. Scan patterns of separations of 6-thiopurines, following the mobile phase sequence of 
Table I (injected volume 195 μ\). (A) Blanks of plasma, CSF and urine samples; (B) plasma, 
CSF and urine samples, spiked with 6TU (1), 6TX (2), 0.7 μΜ 6TG (3), 0.4 μΜ 6MP (4), 
0.4 μΜ 6MPR (5) and 0.7 μΜ 6TGR (6). 6TX and 6TU are products of xanthine oxidation 
reaction on 6MP. The absorption is expressed in absorbance units (AU). The scale is 
indicated in the figures. 
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TABLE I 
MOBILE PHASE SEQUENCE USED FOR SEPARATION OF 6-THIOPURINES 
A = 0.025 M phosphoric acid, pH 2.75; В » methanol 50% (v/v);and С = 0.10 M potassium 
dihydrogen phosphate, pH 6.6. 
Time 
(min) 
0.0 
5.0 
10.0 
20.0 
A 
(%,v/v) 
100.0 
98.0 
30.0 
30.0 
В 
(%, v/v) 
0.0 
2.0 
3.5 
3.5 
С 
(%, v/v) 
0.0 
0.0 
66.5 
66.5 
Chromatography was carried out on two columns in series, at a constant 
flow-rate of 1.7 ml/min and at a temperature of 33 ο 0 (in a water bath). 
To achieve a separation such as seen in Fig. 1, we eluted with 0.025 M 
phosphoric acid (pH 2.75), methanol 50% (v/v) and 0.10 M potassium 
dihydrogen phosphate (pH 6.6) following the mobile phase sequence of Table 
I. The eluents were degassed before and during HPLC runs by continuous 
helium purging. Before use, solutions were filtered through a Millipore filter 
(type HA, pore size 0.45 μτη). Total run time (including equilibration time for 
the next run) was 40 min. It is advisable to wash columns with methanol 50% 
(v/v) after several runs. Depending on the injected volume, 195 μί от 500 ці, we 
wash the columns after every twenty or ten runs, respectively. 
Stock solutions 
The 6-thiopurines were dissolved in 0.025 M potassium dihydrogen 
phosphate and the solutions were adjusted to a pH of about 11 with 4.0 M 
potassium hydroxide. After the 6-thiopurines had dissolved completely, the 
solutions were re-adjusted to a pH between 6.5 and 7.0 with 4.0 M phosphoric 
acid and diluted to a thiopurine concentration of 0.1 mg/ml. Before addition 
of DTT (final concentration 60 mg/1), 20 μί of each solution were diluted to 
500 μί with 0.05 M potassium dihydrogen phosphate pH 4.6, and the exact 
thiopurine concentrations were determined spectrophotometrically. 
Parameters on which the exact concentrations were calculated are [11]: 
6MP: Х
т а х
 = 322 nm, e
m a x
 = 21.5 т З Г 1 cm" 1 . 6TG: X
m a x
 = 342 nm, e
m a x
 = 
25.6 mAT1 cm" 1 . 6MPR: X
m a x
 = 322 nm, e
m a x
 = 27.6 mM'1 cm'1. 6TGR: 
bmax = 342 nm, emax = 26.7 mM - 1 c m - 1 . 
Stock solutions kept at a temperature of 4° С were stable for at least two 
weeks. 
Enzymatic preparation of 6-thioxanthme (6TX) and 6-thiouric acid (6TU) 
6-Mercaptopurine was catabolized enzymatically by xanthine oxidase (EC 
1.2.3.2) into 6TX and 6TU according to the procedure described by the 
manufacturer of the enzyme. 
Sample preparation 
Venous blood samples of 2 ml were collected in tubes containing heparin 
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plus 120 ßg of DTT. After mixing, the blood samples were centrifuged (5 min, 
2000 g) and plasma was pipetted into micro test-tubes (type 3810, Eppendorf, 
Hamburg, F.R.G.). CSF samples of 0.5 ml were collected in micro test-tubes 
containing 30 ßg of DTT. Plasma and CSF samples were put on ice and 
deproteinized by adding one-tenth of the sample volume of freshly prepared 
ice-cold 50% (w/v) trichloroacetic acid (TCA). 
From the urine samples, 2 ml were taken and pipetted into tubes containing 
120 /ig of DTT. The urine samples were filtered through a Millipore filter (pore 
size 0.22 μπα) before measurement. 
DTT was added to increase the stability and the recovery of the assay [ 1 , 8 ] . 
If not measured immediately, extracts of all samples were stored refrigerated 
and analysed within two weeks, since with older solutions additional 
absorption peaks were observed. 
Thiopurine solutions for intravenous injection 
Solutions for intravenous injections were freshly prepared; 6MP or 6TG was 
dissolved in 0.178 M sodium bicarbonate to which sodium hydroxide was 
added until the thiopurine had dissolved completely. The pH of the final 
solution was about 10. Intravenous injection was performed through a sterile 
Millipore membrane filter, type Millex GS (pore size 0.22 /im). 
RESULTS AND DISCUSSION 
Stability and recovery 
As discussed previously [1] thiopurines are poorly soluble at low pH. At 
basic pH solubility is much better, but oxidation of the SH group has to be 
prevented by addition of, for example, DTT [1, 8 ] . With the extraction 
procedure used, the recovery of thiopurines added to plasma is 94% [1] . 
Quantitation and calibration 
Calibration curves were made using standard solutions of known concentra­
tions. Peak areas of 6MP and 6MPR were integrated at 312 nm, peak areas of 
6TG and 6TGR were integrated at 342 nm. Peak areas were calculated in mm2 : 
peak area = peak height X peak width at half height. The relationships we 
found between concentrations and integrated areas and the corresponding 
TABLE II 
CALCULATION FACTORS FOR CALIBRATION CURVES OF 6-THIOPURINES 
Concentrations are given in μΜ, areas in mm3, optical scale = 0.01 absorbance units at 10 
mV, and injected volume is 195 μΐ. 
Thiopurine Concentration factor Correlation coefficient 
6MP Cone. - (area x 0.006938) + 0.002873 0.9999 
6MPR Cone. » (area X 0.009792) — 0.028761 0.9989 
6TG Cone. •= (area x 0.008236) - 0.001824 0.9997 
6TGR Cone. «= (area X 0.009714) + 0.021746 0.9995 
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correlation coefficients are given in Table II. V'ith an injected volume of 500 
μΐ, we found a lower limit of detection for 6MP, 6TG, 6MPR and 6TGR of 
20 nM, 25 ηΛί, 65 nM and 60 ηΛί, respectively. 
For 6TX and 6TU, no calibration curves have been made because of the lack 
of purified 6TX and 6TU. 
Accuracy, precision and reproducibility 
The accuracy of the method was evaluated by analysing plasma samples 
containing known amounts of 6MP, 6MPR, 6TG and 6TGR in a concentration 
range of 100—5000 ηΛί. The 95% confidence intervals for single determinations 
of the thiopurines in plasma were calculated, using the i-value from a one-tailed 
Student's f-distribution table and the variance of absolute differences between 
the actual concentrations (100, 250, 500,1000, 2000 and 5000 ηΛί, respective­
ly) and the concentrations found. The results indicate that any found value 
would fall within approx. 17.3%, 18.6%, 21.4% and 25.9% of its true value in 
experiments with 6MP, 6TG, 6MPR and 6TGR, respectively. The validation of 
¿Γ 5 Ю 15 mm 5 Ю 15 mn <r 5 10 15 min 
Fig. 2. Scan patterns of plasma, CSF and urine samples (injected volume 195 μΐ) of a goat, 4 
h after an intravenous injection. (A) 6MP (20 mg/kg body weight), urine sample is diluted 
5000 times before injection; (B) 6TG (5 mg/kg body weight), urine sample is diluted 25 times 
before injection. For absorbance units and for identification of the peaks, see legend of Fig. 
1. 
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the method was applied to plasma at the concentrations mentioned above, by 
determination of the precision (within-day variability) and of the reproducibili­
ty (day-to-day variability). 
The coefficient of variation for the within-day variation (n = 5) at any 
concentration of 6MP, 6TG, 6MPR and 6TGR was in the range 1.4—1.7%, 
2.1—8.7%, 2.8—10.6% and 3.2—12.5%, respectively. The day-to-day variation 
(days 1—3) for the same set of data was in the range 2.3—6.0%, 2.8—7.3%, 
4.5-9.4% and 4.9-11.8% for 6MP, 6TG, 6MPR and 6TGR, respectively. 
Analysis in biological fluids 
The method has been applied to the measurement of concentrations of thio-
purines in several body fluids after administration of 6MP or 6TG to a goat by 
an intravenous bolus injection. Scan patterns of analysis in plasma, CSF and 
urine show the presence of 6MP and 6MPR (Fig. 2A). Chromatographic plots 
of samples taken after administration of 6TG are given in Fig. 2B. In Fig. ЗА 
and B, time-dependent concentration curves can be seen after push injection of 
6MP and 6TG, respectively. 
The concentrations of the ribosides of both 6MP and 6TG are higher than 
the concentrations of the parent compounds. The concentration—time curves 
of the parent drugs only are far short of representing the total biologically 
active compounds, at least in goats. In man, it was demonstrated that 6MP and 
6MPR are equitoxic at equimolar doses, when given intravenously [12]. 
E • 
10; 
01: 
9 h 
Fig. 3. Concentration—time curves of plasma levels in a goat after an intravenous injection. 
(A) 6MP (20 mg/kg body weight); (*) 6MP, (•) 6MPR. (B) 6TG (5 mg/kg body weight); (*), 
6TG;(· ) , 6TGR. 
CONCLUSIONS 
In this paper we describe an HPLC procedure to measure 6MP, 6TG, 6MPR 
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and 6TGR in one single run. The sensitivity of the method enables the 
pharmacokinetic behaviour of 6-thiopurines in plasma, CSF and urine to be 
followed for several hours. Since the introduction of HPLC many applications 
for thiopurines have been reported [2—10]. Several extraction methods do not 
seem optimal since low recoveries are found [8, 9 ] . To prevent oxidation of 
the mercapto (SH—) group of the thiopurines, DTT is added to standards and 
samples [1, 8 ] . Other measures have to be taken against oxidation of the thio­
purines. Therefore the extraction procedure should be kept short and simple, 
and should be performed in the cold. The stabilizing effect of DTT increases 
recovery to 94% [1] , and together with all other optimized conditions of 
sample preparation and chromatography a sensitive and reliable method has 
been created to measure 6-thiopurines. From our study it may be concluded 
that all studies on pharmacokinetics of 6MP and 6TG in all kinds of species, 
including man, should be completed by involving all biologically active deriva­
tives of 6-thiopurines. 
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CHAPTER IV 
6-MERCAPTOPURINE: 
PLASMA AND CSF CONCENTRATIONS DURING MAINTENANCE TREATMENT OF CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKAEMIA 
Schouten TJ, Abreu RA De, Bruyn CHMM de, Kleijn E van der, Oosterbaan 
MJM, Schretlen EDAM, Vaan GAM de. Published in essence in: Adv Exp Med 
Biol 1984;1658:367-370 
INTRODUCTION 
6-Mercaptopurine, an antimetabolite and an S-phase specific agent, is 
used extensively in the maintenance treatment of childhood ALL (1, 2). 
In essence, the dose, way and schedule of administration have remained 
unchanged from the time the drug was introduced in clinical practice (1, 
2, 3). The low oral dose necessitates the availability of a very sensi­
tive and specific method of measurement when studying plasma concentra­
tion-time curves. De Abreu et al have developed such a method based on 
high-performance liquid chromatography (Chapter II, 4). The lower detec­
tion limit is approximately 3 ng/ml or 0.016 μΜ. The addition of dithio-
threltol (DTT) remarkably increased the stability of 6MP, and the avera­
ge recovery of standards added to plasma increased from 20% (without 
DTT) to 94% (with 60 pg DTT per ml plasma). 
In an earlier and orientating phase of our studies, we used this method 
to determine 6MP plasma and CSF concentrations in patients receiving 
maintenance treatment of ALL. The schedule of administration of the 
maintenance therapy was in accordance with the operative protocol V of 
the "Stichting Nederlandse Werkgroep Leukemie bij Kinderen"(Dutch Child­
hood Leukaemia Study Group) (Fig.l). In this protocol maintenance treat­
ment is administered in cycles of seven weeks. During the first five 
weeks 6MP is given daily in an oral dose of 50 mg/m2 in combination with 
methotrexate (MTX) 30 mg/m2, that is also given orally. On the first day 
of the cycle a first dose of MTX is administered and subsequently this 
is repeated weekly. During the last two weeks of the seven-week cycle, 
prednisone Is given daily in an oral dose of 40 mg/m2. In those two 
weeks vincristln in a dose of 2.0 mg/m2 is given weekly instead of MTX 
("consolidation treatment"). Subsequently the seven-week cycle is repea­
ted. On the first day of a new cycle one starts with both 6MP and MTX 
and then continues as described above. 
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MATERIALS AND METHODS 
Plasma and CSF samples were obtained during routine clinical investiga­
tions, performed according to protocol V of the "SNWLK". In this proto­
col lumbar punctures are required every 14 weeks on the first day of the 
two weeks of prednisone and vlncristin consolidation (flg.l). To study 
6MP concentrations In CSF an amount of ± 1.5 ml of CSF was withdrawn. On 
the same occasion venapunctures were performed to inject vlncristin and 
to obtain blood for routine clinical chemistry. An amount of blood, ± 6 
ml, was taken to quantitate 6MP in plasma. The patients were not addi­
tionally burdened, for the punctures had to be done anyhow, and the 
volume of the samples was limited. All samples were obtained approxima­
tely 24 hours after the last daily dose of 6MP. 
Both CSF and blood samples were withdrawn into heparinized tubes, con­
taining DTT, and chilled immediately at 0oC. Samples were deproteinized 
and stored at 40C until analysis. The analysis was performed as descri­
bed in Chapter II (4). 
S N W L K 
SCHEMA ALL-PROTOCOLS A 
BEHANDELING DOSIS 
SCHEDEL 
BESTRALING 
MTX PRED 12.5 mg/m'/keer ι th 
VCR 2 m g / m V w k ι ν 
PRED 4 0 mg/mVdag or 
L ASP 2 0 0 E/kg/dag ι ν 
6-MP 50 mg/mVdag or 
MTX 30 mg/m'/wk or 
BMP 
LP 
WEKEN 
FORMULIER 
DATUM 
INDUCTIE C Z S ONDERHOUDSBEHANDELING 
RADIO THERAPIE 
ttttt 
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m 
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Fig . 1. Treatment scheme of arm A from the protocol ALL V (SNWLK). 
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RESULTS 
The concentrations of 6MP in plasma and CFS obtained on day 35 of a 
maintenance treatment cycle, are depicted graphically in fig. 2. The 
mean plasma 6ЙР concentration was 0.064 μΜ, with a range of 0.020-0.140 
μΜ. The mean CSF concentration was 0.029 μΜ with a range of 0.018-0.050 
μΜ. The ratio of the mean 6MP concentration in CSF over the mean 6MP 
concentration in plasma is approximately 0.40. Plasma and CSF concentra­
tions simultaneously obtained from individual patients are shown in 
fig.3. 
The plasma and CSF concentrations measured and depicted in the figures 
are close to the limit of detection, and several other samples gave ne­
gative results. 
In plasma samples obtained during interruption of the administration of 
6MP for prednisone-vincristin consolidation, or after stopping mainte­
nance treatment, 6MP was often still present 1-4 weeks after the last 
dose of 6MP. 
• 
• 
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plasma CSF 
Fig. 2. Graphic representation of 6MP concentrations in plasma and CSF 
from ALL patients receiving maintenance treatment. Samples were obtained 
± 24 hours after the last of 35 daily oral doses of 6MP. 
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plasma CSF 
Fig. 3. The simultaneously obtained 6MP concentrations in plasma and CSF 
in individual patients are connected by broken lines. See also legend to 
Fig.2. 
DISCUSSION 
The concentrations measured in plasma and CSF were relatively low, as 
compared with the concentrations, i.e. 100-200 μΜ, used in in vitro stu­
dies (5, 6, 7). The actual presence of 6MP in CSF in a concentration ra­
tio of approximately 0.40 to simultaneously measured plasma concentra­
tions was an important finding. In older studies by Loo et al and Nelson 
et al penetration of 6MP into CSF could not be demonstrated (8, 9). On 
physicochemical grounds however, one would expect reasonable penetration 
of 6MP (10). Our finding of penetration of 6MP into CSF was only possi­
ble because of the sensitivity and specificity of our method. 
It was impossible for us to study the intravenous administration of 6MP 
in patients. There was no formulation of 6MP available to us which was 
suitable for intravenous administration to humans. It is for this rea­
son, that we performed our studies on intravenous administration in ex­
perimental animals (Chapters V, VI, VII, VIII). 
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By increasing the dose rate and prolonging the duration of administra-
tion we tried to simulate the high concentrations during prolonged pe-
riods of time, which were found necessary in in vitro studies (5, 6, 7). 
These latter studies have shown also that 6TG is a more potent antimeta-
bolite than 6MP, and more important, 6TG is maximally effective at a 
much lower concentration, i.e. 1 to 2 yM for 6TG vs. 100 to 200 yM for 
6MP (7). As these in vitro cytolytic concentrations of 6TG seem to be 
attainable in patients treated with moderate doses of 6TG (11), this 
drug was included in the second part of our studies (Chapter III, VII). 
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CHAPTER V 
6-MERCAPTOPURINE: ORAL ADMINISTRATION AND I.V. BOLUS INJECTIONS IN DOGS 
Schouten TJ, Abreu RA De, Schretlen EDAM, Bruyn CHMM de, Kleijn E van 
der, Oosterbaan MJM, Vaan GAM de. Accepted for publication in: Eur Pae-
diatr Haematol Oncol 1985 
ABSTRACT 
6-Mercaptopurine (6MP) levels in serum of dogs were studied after long-
term oral administration and intravenous injection. 
During long-term daily oral administration of 50 mg of 6MP more or less 
constant levels of 6MP have been found after 1-3 weeks. After stopping 
the administration of the drug, 6MP concentrations remained constant for 
a further period of 3-6 weeks and then declined within 1-2 weeks below 
the limit of detection. 
I.v. bolus injections of 50 mg of 6MP resulted in concentration versus 
time curves which fitted into an open two-compartment pharmacokinetic 
model. Half-life times were in a range of 13-21 and 125-151 minutes, 
respectively. Peak concentrations were from 2,500 to 10,500 nmol/1. 
Our data on i.v. push injections with a customary clinical dose revealed 
peak concentrations which were low in comparison to the concentrations 
used in in vitro studies by Tidd and Paterson to achieve maximal cell-
kill. Moreover, the half-life times of the 6MP after i.v. bolus injec-
tions are short, so prolonged high plasma concentrations are not obtai-
ned by i.v. bolus injections. 
We suggest that prolonged infusions of 6MP, at relatively high dose ra-
tes should result in higher and persisting plasma concentrations and so 
should promise a more potent antitumor activity. 
Keywords: 6-Mercaptopurine 
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INTRODUCTION 
Nowadays 6-mercaptopurine (6MP) is used mainly for maintenance treatment 
of acute lymphoblastic leukaemia (ALL) (1). The first study on the phar-
macokinetics has been published in 1954 (2). However, such studies have 
remained rather scanty (3), because radioactively labeled 6MP is not 
suitable for widespread use. Other methods to quantitate 6MP were also 
not readily applicable because large amounts of plasma were necessary 
(4, 5). Moreover, relatively high i.v. doses had to be used in order to 
obtain measurable concentrations, although daily oral administration at 
much lower doses is clinical practice (1). 
In recent years several specific and sensitive methods for the determi-
nation of 6MP and related drugs have been reported (6, 7, 8, 9). We de-
veloped a method (9) to study the pharmacokinetic behaviour of 6MP at 
the customary oral and low dose levels. Along with initial observations 
on children with ALL (10), we started to explore the pharmacokinetics of 
6MP in laboratory animals. 
In the present study we report on observations in dogs; we adapted our 
experiments to the clinical practice in ALL. We determined plasma 6MP 
concentrations during and after long-term daily oral administration of 
the drug. Also concentration-time curves were obtained after i.v. bolus 
injections of the same dose as used in the long-term experiments. We 
varied the schedules of drug administration because of the explorative 
nature of the study. 
From our findings, and after re-interpretation of data from the litera-
ture, we conclude that the therapeutic use of 6MP, and obviously also of 
other thiopurines in man, is based on tradition rather than on solid ex-
perimental grounds. Suggestions are made to develop a more rational do-
sing and administration of thiopurines. 
MATERIALS AND METHODS 
Experimental animals 
Labrador dogs were selected for reasons of availability, cost, and num-
ber and volume of blood samples to be obtained during short- and long-
term experiments. The dogs used in our experiments were bred by the Cen-
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trai Animal Laboratory of the Catholic University of Nijmegen. All dogs 
were fathered by the same animal. At the time of the experiments the 
dogs, of either sex, were between 10-26 months of age and 20.5-29.0 ki­
lograms of weight. 
Dose and ways of 6MP administration 
To avoid problems in pharmaceutical formulation and in oral administra­
tion of the drug tablets of 50 mg, which are commercially available, we­
re used. Tablets are easily swallowed by dogs. For reasons of uniformity 
it was decided to use the same 50 mg dose for determining concentration-
time curves after i.v. bolus injections. 
Chemicals 
τι 
Standard tablets of 50 mg (Purinethol , Wellcome) were used, when 6MP 
was given orally . For i.v. injections 6MP was obtained from Fluka AG 
(Buchs SG, Switzerland). The 6MP solutions for i.v. administration were 
prepared freshly; 60 mg of 6MP were dissolved in 0.25 ml of a 5.0% solu­
tion of sodium hydroxide and diluted with a sterile 0.9% sodium chloride 
solution as described previously (9). Before 6MP was added, helium was 
flushed through the solutions in order to prevent oxidation of 6MP. A 
dose of 50 mg of 6MP was injected through a Millipore membrane filter, 
type Millex-GS (pore size 0.22 um). 
Preparation of samples for 6MP determination 
Blood samples were drawn from a catheter inserted into a jugular vein or 
by repeated venapuncture, depending on the number of samples to be taken 
on the day of the experiment and the feasibility of insertion. Samples 
of 5 to 6 ml were collected in tubes containing heparin and 300 ug di-
thiothreitol (DTT) to stabilize 6MP. After mixing, the blood sample was 
centrifuged (5 min, 2,000 χ g). One ml of plasma was transferred in du­
plicate with a calibrated syringe into microtest tubes (type 3810, Ep-
pendorf, Hamburg, GFR) and kept on ice for 5 minutes. Protein was pre­
cipitated by the addition of 0.1 ml of ice-cold trichloroacetic acid 
(TCA) 50% w/v. After shaking vigorously, the tubes were kept on ice for 
another 10 minutes and centrifuged (10 min, 2,000 χ g). 6MP was quanti-
tated with a Spectra Physics SP-8000 high pressure liquid Chromatograph 
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as described previously (9). The concentrations of 6MP are expressed in 
nmol/1. 
Analysis of pharmacokinetic data 
After an i.V. bolus injection, as the very first dose of 50 mg of 6MP, 
plasma concentration profiles were fitted into an open two-compartment 
pharmacokinetic model by standard procedures (11). Pharmacokinetic para-
meters were calculated on an HP 9810 calculator (Hewlett Packard). 
RESULTS 
A concentration-time curve obtained after a first oral dose of 6MP show-
ed a "peak" plasma concentration some 4 to 5 hours after administration 
of a 50 mg tablet (Fig. 1). 
6MP 
nmol/l -
Fig. 1. Concentration versus time curve after a first oral dose of 6MP; 
50 mg as a standard tablet. Lower limit of detection is 16 nmol/1 
(broken line). 
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6MP 
(nmol/|) 
250-
dog 648 
dog 659 
dog 660 
dog 661 
dog 662 
- last dose 
Fig. 2. Concentrations of 6MP in plasma during long-term daily admini-
stration. Blood was drawn just before the dogs received another daily 
dose of 50 mg. Lines start on the first day of administration and stop 
at the day of the last dose of 6MP. (For exact treatment schedule see 
table 1; lower limit of detection, 16 nmol/1, is represented by the 
broken horizontal line). 
The results after long-term daily administration of 6MP were somewhat 
surprising. Due to the explorative nature of the study, treatment sche-
dules were diverse, (table 1). After 1-2 weeks of daily oral 6MP, a "re-
sidual" concentration of 6MP could be measured in plasma before the dogs 
received another daily dose of 6MP (fig. 2; dogs 648, 661, 662). Daily 
i.v. bolus injections of 6MP during 10 days did not lead to accumulation 
of the drug, but subsequent oral administration did (dogs 659, 660). The 
steady state concentrations varied in individual dogs. Moreover, after 
stopping the prolonged daily administration of 6MP, the level in plasma 
remained more or less constant for 3-6 weeks. After that period a rapid 
decline in the concentrations of 6MP to below the limit of detection 
occurred (fig.3). 
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TABLE 1. 
DURATION AND WAY OF DAILY ADMINISTRATION OF 50 MG 6-MERCAPTOPURINE 
dog 6MP in mg/kg 
number body weight duration and way of administration 
648 1.7 45 days; oral except day 27, when an i.v. injec­
tion was given 
659 2.2 28 days; i.v. days 1 - 1 1 and day 24, oral days 
12 - 23 and 25-28 
660 2.2 25 days; i.V. days 1 - 1 1 and day 22, oral days 
12 - 21 and 23 - 25 
661 1.8 30 days; oral except days 1 and 29, when I.v. in­
jections were given 
662 2.2 18 days; oral except days 1 and 15, when i.v. in­
jections were given 
TABLE 2. 
6-MERCAPTOPURINE KINETICS FOLLOWING A FIRST DOSE OF 50 MG INTRAVENOUSLY 
dog 6MP in mg/kg t, ,1 (corr) t, ,2 (corr) V V A.U.C. 
number body weight (min) (min) (1) (1) (nmo].h/l) 
647 1.8 20.9 (0.99) 130.4 (0.97) 83.8 154.7 2512 
659 2.2 17.0 (0.99) — 17.2 — 7799 
660 2.2 18.0 (0.99) 125.2 (0.98) 21.0 34.8 7658 
661 1.8 13.1 (0.99) 135.6 (0.95) 74.0 169.1 1681 
662 2.2 19.9 (0.99) 151.1 (0.99) 65.2 138.5 3141 
Τ, , 1 and t. , 2: first and second half-life time according to an open 
two-compartment model. V and V : volume of the central compartment and 
apparent volume of distribution, respectively; AUG indicates area under 
the curve, (corr): correlation coefficient. 
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Fig. 3. Disappearance curves of 6MP from plasma. The curves start at the 
moment of stopping the administration of the drug. (For exact treatment 
schedule see table 1; lower limit of detection, 16 rnnol/l, is repre­
sented by the broken horizontal line). 
The pharmacokinetic data obtained in 5 dogs, after a first dose of 50 mg 
of 6MP by i.v. injection, are summarized in table 2. A typical concen­
tration-time profile is depicted in fig. 4A. Plasma levels of 6MP peak 
at values of 2,500-10,500 nmol/1. This concentration of 6MP declines to 
less than 100 nmol/1 within 3 to A hours. A first half-life time (t, , 1) 
was calculated with a range of 13-21 minutes. The second half-life time 
(t. , 2) has a range of 125-151 minutes. The volumes of the central com­
partment (V.), the apparent volumes of distribution (V,), and the areas 
under the curve (AUC) have a rather wide range. 
Concentration-time curves after i.v. bolus injection, obtained during 
long-term daily oral application of 6MP (fig. 4B,C) are quite different 
from the curve after a very first dose i.v. (fig. 4A). 
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During long-term administration we could not demonstrate any pronounced 
hematological toxicity. The observed tendency to a slight decrease in 
hemoglobin concentrations could be due either to the effect of frequent 
blood sampling, or to an effect of 6MP. White blood cell and thrombocyte 
counts did not change appreciably. In most dogs a rise in alanine amino­
transferase (ALAT) activity became apparent, whereas aspartate amino­
transferase (ASAT) and alkaline phosphatase activities did not change. 
Serum urea and creatinine levels remained constant. After stopping 6MP 
administration ALAT activity returned to normal values. It was remark­
able that ALAT activity normalized before plasma 6MP levels declined. 
Administration of 6MP did not influence the low to undetectable blood 
levels of uric acid. 
6 hr 
I h — I 1 1 1 1 1 
0 2 4 6 hr 
I 1 1 1 1 -
6 hr 
Fig. 4. Concentration versus time curves after 50 mg of 6MP i.v. by bo­
lus injection. 
A. Very first dose 
j5. Second i.v. dose; between the first and second i.v. bolus injection 
50 mg of 6MP was given orally and daily for ten days. 
C^ . Third i.v. dose; between the second and the third i.v. bolus injec­
tion 50 mg of б MP was given once daily orally for ten days again. 
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DISCUSSION 
This study of 6MP in dogs has revealed a rather peculiar finding i.e. 
the persistence of low concentrations of 6MP in plasma for 3-6 weeks 
after stopping the long-term oral administration of the drug (fig. 3). 
A similar phenomenon has been observed in children, who had received 6MP 
for treatment of ALL (own unpublished observations). 
This implicates a kind of deposit of the drug, the nature of which is 
not clear. The tight binding of 6MP to proteins, either in plasma or li-
ver cells, may be of importance (12, 13, 14). This binding could also 
explain why not all of the 6MP is catabolized to 6-thioxanthine and 
6-thio-uric acid. The steady state concentrations of 6MP after oral ad-
ministration are much lower than the concentrations which have a cytoly-
tic effect in vitro (15). 
The concentration-time curve after a first oral dose of 6MP in tablet 
form, revealed a low and late appearing peak of 6MP in plasma (fig. 1). 
Because of the peculiar shape of the curve and the low concentrations 
obtained in comparison with in vitro cytotoxic concentrations (15), we 
did not explore this further in dogs. Moreover, it had been reported al-
ready, that the bioavailability of 6MP after oral administration is low 
in Rhesus monkeys (16), and this was confirmed in patients with ALL re-
cently (17). 
After a very first dose of 50 mg of 6MP by i.v. bolus injection, the 
concentration-time curves fitted best into a standard two-compartment 
open model (11).The doses were slightly different on a mg/kg body weight 
basis, making calculation of means difficult. The broad variation in 
pharmacokinetic parameters is apparent from the data (table 2). 
Concentration-time curves after i.v. bolus injections, obtained during 
long-term oral use of 6MP, were quite different from curves obtained af-
ter a first i.v. dose of 6MP (fig. 4B,C versus fig. 4A). The exact im-
pact of this change in pharmacokinetic behaviour after pretreatment with 
6MP is unclear. Future studies in humans should consider the influence 
of previous exposure to 6MP on the pharmacokinetic behaviour. 
This and other studies on the pharmacokinetics of 6MP have shown that 
plasma concentrations of 6MP are short-lived after i.v. bolus injections 
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(2, 4, 5, 16, 17, 18). Moreover, at conventional doses of 50 to 100 
2 
mg/m , peak concentrations are rather low in comparison with in vitro 
maximally effective concentrations (15). In vitro data on thiopurines 
have clearly demonstrated that, in order to obtain a maximal cell 
killing effect, cells should be exposed to relatively high concentra-
tions, and this for prolonged periods of time (15, 19). 
Considering the low bioavailability of 6MP after oral administration and 
the rather low and short-lived plasma concentrations after i.v. bolus 
injections in conventional doses, we suggest that prolonged infusion of 
6MP in higher doses should be more effective. The feasibility of this 
approach has already been demonstrated by us in further animal experi-
ments (20). Moreover, this new way of administration of 6MP may lead to 
new indications for the drug. Good penetration of 6MP into CSF has been 
predicted (21) and demonstrated (10, 18, 20). Thus 6MP might play a role 
in the prophylaxis and treatment of CNS leukaemia and CNS tumours. 
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CHAPTER VI 
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ABSTRACT 
In order to study the body distribution of 6-mercaptopurine (6MP), 
Γ H 1 
18- CI -6MP was given by infusion to Marmoset monkeys at a dose rate 
of 5 mg/kg body weight/hour for one and four hours, respectively. Both 
experimental animals were sacrificed two hours after the end of the drug 
Infusion and instantly frozen at -70oC. Whole body sagital sections were 
made later. During the experiments blood samples were obtained regularly 
to quantitate 6MP, 6MP riboside (6MPR), 6-thio-xanthlne and 6-thio-uric 
acid in plasma. 
14 
The autoradiograms revealed extensive distribution of the С label. 
High levels of radio activity are seen in liver, bile and intestinal 
contents. Labelling of the central nervous system and bone marrow is 
obvious. The plasma concentration-time curves of 6MP and 6MPR attain 
steady state concentrations of 30-40 μΜ and 6-12 μΜ respectively. After 
stopping the infusion of the drug, the concentrations of 6MP and 6MPR 
get equal. 6MPR contributes to the biological effect of 6MP, as degrada­
tion of 6MPR results in 6MP. 
In studies on the pharmacokinetics and dynamics one should include all 
relevant metabolites of 6MP, both In plasma and in the cells. 
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INTRODUCTION 
The purine antagonist, 6-mercaptopurine (6MP) is still used in the 
treatment of acute lymphoblastic leukaemia in essentially the same way 
as was initially described by Burchenal in 1953 (1, 2). The rationale of 
the customary oral administration has been questioned recently, because 
pharmacokinetic studies revealed a very low bioavailability of the drug 
after oral administration (3, 4, 5). In each individual target cell 6MP 
has to be metabolized before a cytotoxic effect can be exerted (6, 7). 
Some of the various metabolites produced are present only intracellular-
ly like the nucleotides of 6MP, while others like 6MP riboside (6MPR), 
6-thio-xanthine (6TX) and 6-thio-uric acid (6TU) can also be found in 
plasma. 
In order to gain insight into the distribution of 6MP throughout the 
Γ 14 1 
body, 18- CI -6MP was given to two Marmoset monkeys by infusion. The 
arguments for i.v. infusions have been discussed extensively by us. 
These experiments are part of a series of investigations on 6MP (8, 9, 
10, 11, 12). In this paper we present whole body autoradiograms, and 
concentration-time curves of 6MP, 6MPR, 6TX and 6TU in plasma. These 
metabolites of 6MP were not considered in other recent studies in 
monkeys and humans (3, 4, 5, 13, 17). 
MATERIALS AND METHODS 
Experimental animals 
Two male adult Marmoset monkeys (Callithrix jacchus) were used with a 
body weight of 340 and 315 grams, respectively. The animals were 
anaesthesized by ketamine HCl (40 mg/kg body weight i.m.) and fluothane. 
Intravenous drug administration and arterial blood sampling was 
accomplished through surgically implanted catheters in the femoral ves­
sels. The monkeys were artificially ventilated during the total experi­
mental period. A tracheal canule, placed by tracheotomy was connected to 
an Amsterdam Infant Ventilator (Loosco, Amsterdam, the Netherlands). 
A mixture of oxygen and dinitrogen oxide, admixed with 0.5-1.0% of fluo­
thane was administered. Supplemental ketamine HCl has been given i.m. in 
amounts of 0.1 ml, equivalent to a dose of 10 mg. At the end of the ex-
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periments the animals were sacrificed by an overdose of fluothane. The 
corpses were immersed immediately after sacrifice in cyclopentane, chil­
led to -70°C by the preceding addition of solid CCL. 
Whole body sections for autoradiography were made according to a method 
described previously (14). 
Dose and schedule of 6MP administration 
A dose of 5mg/kg/hour was given in each experiment. Monkey I received a 
one hour infusion and monkey II a four hours infusion. Both experiments 
were terminated two hours after the end of the infusion of the drug. 
8- С -6MP, with a specific activity of 1.7 mCi/mmol was used (Amersham 
Nederland BV, Utrecht, the Netherlands). In the second experiment the 
specific activity was lowered to 0.8 mCi/mmol by addition of unlabelled 
6MP. 
Determination of 6MP and metabolites 
During and two hours after infusion of the drug, blood samples of 0.3 ml 
were collected in micro-test tubes containing heparin and dithiotreitol. 
After chilling on ice, plasma was separated by centrifugation. 
The plasma samples were stored at 4°C; aliquots of 10 or 20 yl were in­
jected onto a reverse phase HPLC column and separation was performed 
according to a method described previously (8). 
Column effluents were collected in small fractions. The radioactivity of 
the various fractions was quantitated by scintillation counting (Searle 
Mark III system, Searle Analytic Inc. DesPlaines, II, USA). The calcu­
lated 6MP, 6MPR, 6TX and 6TU concentrations are based on scintillation 
counting and corrected for dilution with unlabelled 6MP, counting effi­
ciency and quenching. 
RESULTS 
Autoradiographic findings 
14 
The whole body autoradiograms show wide distribution of the С labelled 
6MP and 6MP metabolites throughout the body (figs.l and 2). Especially 
the activity found in the liver, gall bladder and intestinal lumen is 
intense. Other secretory organs, like salivary and lachrymal glands, al-
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Fig. 1. Autoradiogram of a 30 um sagittal section of a Marmoset monkey. 
In this experiment 6-mercaptopurlne at a dose rate of 5 mg/kg/hour was 
given during one hour. Two hours later the animal was sacrificed and 
frozen instantly. Magnification: 0.50. 
Fig. 2. Autoradlogram of a 30 μιη sagittal section of a Marmoset monkey. 
In this experiment 6-mercaptopurine at a dose rate of 5 mg/kg/hour was 
given during four hours. Two hours later the animal was sacrificed and 
frozen instantly. Magnification: 0.50. 
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and 6TU ("^ ). An infusion with a dose rate of 5 mg/kg/hour was given 
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so show a good deal of activity. The appearance of the label in the cen­
tral nervous system is obvious, with a slightly higher labelling of the 
gray matter. Also in the bone marrow the label appears as can be seen in 
the vertebrae. In both experiments the radioactivity is more evident in 
the marrow in comparison with the bony structures. In the heart, activi­
ty is present in the muscular wall as well as in the blood pool. Sec­
tions containing testicular tissue reveal good accumulation of activity 
in these organs. 
In the longer experiment the accumulation of activity is higher in the 
bone marrow. Other differences between the two experiments are not ob­
vious. 
Concentration-time curves of 6MP, 6MPR, 6TX, 6TU in plasma 
Steady state concentrations of 6MP, in the order of 30-40 μΜ, are reach­
ed after half an hour of infusion (figs.3 and 4). Shortly after starting 
the 6MP infusion, 6MPR could be demonstrated. The catabolic products of 
6MP, 6TX and 6TU, also appear rapidly. There is an apparent difference 
in disappearance of 6MP, 6MPR and 6TU from plasma between experiment I 
(fig.3) and II (fig.4). However a more liberal diuresis was present in 
the second experiment, while total doses are different too. During infu­
sion of 6MP the plasma concentration of 6MPR is 20-35% of the 6MP con­
centration, but after termination of the infusion, 6MP and 6MPR get 
nearly the same concentrations. 
DISCUSSION 
The whole body autoradiograms disclosed extensive distribution of ac­
tivity throughout the body (figs.l and 2). The presence of the label in 
the central nervous system (CNS) is of special interest. Older studies 
have denied that 6MP penetrates into the CNS (15). However the physi-
cochemical properties of 6MP are such, that one would expect this drug 
to pass the blood brain barrier (16). Recently we have demonstrated in 
goats that 6MP and 6MPR reach the cerebrospinal fluid in fair amounts 
(12), and others have demonstrated this in Rhesus monkeys (13). Also in 
CSF of ALL patients 6MP has been demonstrated in fair amounts as compa­
red with simultaneously measured plasma concentrations (9, 17). 
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The extensive labelling of the liver, bile and intestinal lumen is a re-
flection of the pivotal role of the liver in purine metabolism. (18). It 
points to a route of elimination of 6MP which is not well-known. Ana-
lysis of bile contents after 6MP infusion may clarify the role of the 
liver in the clearance of thiopurines. Both liver and intestinal mucosa 
are rich in xanthine oxidase, so 6MP itself will probably be catabolized 
to 6TX and 6TU. 6MPR, if present in bile, could give rise to an entero-
hepatic circulation. 6MP is intracellularly anabolized to 6-thio-IMP and 
either further metabolized to other thionucleotides by kinases or degra-
ded to 6MPR by 5'nucleotidase. 6MPR, when released from the cells, can 
only be converted to 6MP. 
The concentration of 6MPR equals the concentration of 6MP after stopping 
the infusion (figs. 3 and 4). The biological importance of 6MPR was de-
monstrated emphatically during high-dose 24 hours infusion in goats (12). 
Ignorance of the presence of 6MPR may have resulted in an underestima-
tion of the bioavailability of 6MP (3, 4, 5). 
The accumulation of radioactivity in bone marrow is especially relevant. 
The bone marrow is the main site of cytotoxic action of 6MP in leukae-
mia. Whether the label is intracellular in the haematopoietic cells of 
the bone marrow or mainly in the peripheral blood pool can only be con-
cluded after further investigations. Ideally one should try to correlate 
intracellular concentrations of cytotoxic products of 6MP with concen-
tration-time phenomena in plasma. 
The ultimate cytotoxic action of 6MP and metabolites is exerted intra-
cellularly, but "an otherwise effective drug will not kill a drugsen-
sitive tumor cell that it cannot (or does not) reach in lethal concen-
trations" (19). 
So determination of plasma concentration-time curves of all relevant me-
tabolites of 6MP will contribute to the design of rational dosage, sche-
dules and ways of administration of this drug. 
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6-THIOGUANINE: HIGH-DOSE TWO HOURS INFUSIONS IN GOATS 
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SUMMARY 
6-Thioguanine (6TG) is poorly absorbed after oral administration. Bolus 
injections of 6TG result in high peak concentrations with relatively 
short-lived plasma concentrations. In vitro studies have shown the im-
portance of prolonged exposure to 6TG. Therefore we administered 6TG by 
infusion at a dose rate of 2 mg/hour during 2 hours. In three goats we 
determined the plasma concentration-time curves of 6TG and its riboside 
(6TGR). 
A steady state was reached for 6TG and was almost reached for 6TGR with-
in the two hours of infusion. In one experiment we obtained several 
samples of CSF and we observed good penetration of 6TG and 6TGR Into 
CSF. Urinary excretion of 6TG and 6TGR was also quantitated. The amount 
of drug and metabolite excreted more than 4 hours after stopping the in-
fusion was negligible. By infusing 6TG, the problems of both erratic ab-
sorption after oral administration and acute renal toxicity after bolus 
injection, can be averted. In our opinion prolonged infusions of 6TG may 
be of advantage in humans suffering from actively proliferating malig-
nant diseases, and thus should be studied. 
FOOT NOTES 
Supported by the "Queen Wilhelmina Fund" (Dutch Cancer Society); Grant 
NUKC KG 81-2. 
Abbreviations 6TG: 6-thioguanine; 6TGR: 6TG riboside (6-thioguano-
sine); 6MP: 6-mercaptopurine; 6MPR: 6MP riboside; 
CSF: cerebrospinal fluid. 
KEY WORDS 
6-thioguanine, 6-thioguanosine, 6-thioguanine riboside, 6-niercaptopu-
rine, thiopurines. 
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INTRODUCTION 
The purine analog and antimetabolite 6-thioguanine (6TG) is used mainly 
in the treatment of acute myeloid leukaemia. The drug itself has no di-
rect cytotoxic effect, but has to be phosphorylated initially by the en-
zyme hypoxanthine guanine phosphoribosyl transferase to 6-thio-GMP. 
The cytotoxic effect is exerted through incorporation into DNA as 6-
thio-dGTP (Paterson and Tidd 1975, Nelson et al 1975, Wotring and Roti 
Roti 1980, Lee and Sartorelli 1981). The influence of 6-thio-GMP, and 
methylated analogs, on the purine de novo synthesis is probably of minor 
importance in the mechanism of cell kill (Nelson et al 1975, Wotring and 
Roti Roti 1980). Under special circumstances however it may be of signi-
ficance (Lee and Sartorelli 1981). 
Pharmacological studies of 6-thioguanine are relatively scarce (LePage 
and Whitecar 1971, Loo et al 1981, Brox et al 1981, Lu et al 1982, Ko-
nits et al 1982). Only recently sensitive and specific analytical me-
thods have been described to quantitate 6TG in biological fluids. We 
developed an HPLC method to determine 6-thioguanine, 6-mercaptopurine 
and their respective ribosides (6TGR and 6MPR) (Van Baal et al 1984). 
The first pharmacological study in humans, using HPLC to detect 6TG in 
plasma after oral administration, revealed a 30-fold range in peak plas-
ma concentrations. Moreover peak concentrations were seldom as high as 
the concentration with optimal cell killing effects in vitro. As a re-
sult of their findings Brox and coworkers seriously question the ratio-
nale of the customary oral administration of the drug (Brox et al 1981). 
Recent in vitro studies demonstrated a predominant S-phase specificity 
of 6TG (Wotring and Roti Roti 1980, Lee and Sartorelli 1981). Thus dura-
tion of exposure is a factor as important as concentration of the drug. 
The administration of drugs by i.v. bolus injections frequently results 
in high peak levels without sustained concentrations of drug in plasma. 
Therefore, in the present study we explored the administration of 6TG by 
infusion. 
MATERIALS AND METHODS 
Experimental animals 
African midget goats were obtained from commercial sources and maintain-
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ed in the Central Animai Laboratory of our University. During a short 
thiopental-induced anaesthesia, catheters were introduced percutaneously 
into both jugular veins; one catheter to administer the drug and one to 
obtain blood samples. Urine catheters were used to collect urine. 
Attempts at inserting a thin catheter in the lumbar space by percutane­
ous puncture were unsuccessful, except in experiment В in which a cathe­
ter functioned, suboptimally, during part of the experiment. 
Dose and administration of 6TG 
In all three .experiments 6TG in a dose of 2 mg/kg/hour was given during 
2 hours. The drug, of analytical grade, was obtained from Fluka, Rotter­
dam, The Netherlands. The desired amount was weighed out in a sterile 
flacon and dissolved by addition of sterile sodium bicarbonate (1.4%) 
and sodium hydroxide. After solution the pH was lowered to 9.8-10.2 by 
addition of chloric acid. The final concentration of 6TG was between 2 
and 3 mg/ml. The solution was infused through Millipore membrane fil­
ters, type Millex GS (pore size 0.22 ym). A liberal and alkaline diure­
sis was established before the infusion of 6TG and maintained untili at 
least two hours after the end of the 6TG infusion. 
Preparation of samples and determination of 6TG and 6TGR 
Blood samples of ± 6 ml were collected in tubes containing heparin and 
dithiothreitol. Sample preparation of blood, urine and cerebrospinal 
fluid (CSF) and analysis was performed according to our HPLC method des­
cribed recently (Van Baal et al 1984). 
RESULTS 
The plasma concentration-time curves obtained during and after the infu­
sion of 6TG in the three experimental animals are depicted in fig.l. In 
all three experiments steady state concentrations of 6TG are present 
within one hour after the start of the infusion. 6-Thioguanosine, the 
riboside of 6TG formed by intracellular metabolism, is present from the 
first sample on. The concentration of 6TGR exceeds that of 6TG within 
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Fig. 1. Concentration-time curves of 6-thioguanine ( • ) and 6-thiogua-
nine riboside (=6-thioguanosine) ( • ) during and after a two hours in­
fusion at a dose rate of 2 mg/kg/hour in three different goats. The dot­
ted lines represent the added concentrations of 6TG and 6TGR. 
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the first hour and tends to a steady state towards the end of the two 
hours Infusion. 
In experiment В several CSF samples, 5 during and 2 shortly after drug 
Infusion, could be obtained. The CSF concentration of 6TG is about 25% 
of thé plasma 6TG concentration towards the end of the infusion. The 
concentration of 6TGR in CSF is then approximately 40%. While 6TGR CSF 
concentrations are still increasing, the 6TGR plasma concentration tends 
to a steady state (data not shown). 
Urine excretion of 6TG and 6TGR was determined in all three animals. In 
fig. 2 the excretion of 6TG in relation to the Creatinin excretion Is 
shown during and after the Infusions. The amounts of 6TG and 6TGR excre-
ted more· than 4 hours after stopping the Infusion of 6TG, are negligi-
ble. In urine the cumulative combined excretion of 6TG and 6TGR was 49% 
in experiment A, 26% in В and 27% in С The overall ratio of 6TG/6TGR in 
urine was 3.1 in A, 5.2 in В and 2.3 in C. 
• В 
2 hours infusion 90 120 180 240 
Fig. 2. Urinary excretion of 6TG relative to creatinine excretion, du­
ring and after a two hours infusion in three different goats. 
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Acute side-effects, like crystalluria, were not observed, because a 
liberal diuresis was maintained. Long-term side-effects could not be ob­
served by routine clinical chemistry and blood counts, performed 2-3 ti­
mes a week for 3 weeks after the experiments. 
DISCUSSION 
In a series of investigations we explored the feasibility of parenteral 
administration of 6-mercaptopurine (Schouten et al 1984, 1985a, 1985b, 
1985c), because the customary oral administration is less reliable (Ding 
and Benet 1979, Zimm et al 1983a, 1983b). We concluded that prolonged 
infusions at relatively high doses are more rational. The feasibility 
was established in goats using 24 hours Infusions of 6MP (Schouten et al 
1985c). We demonstrated excellent penetration of 6MP and 6MPR into CSF 
in goats. Preliminary results of an on-going study in humans have al­
ready been reported and confirm our findings in goats (Zinun et al 1984). 
In the present study we investigated the administration of 6TG by infu­
sion in goats. We found steady state plasma concentrations of 6TG, with 
a range of 2.4-3.5 μΜ, which were reached within the relative short du­
ration of the infusion (fig.l). However the concentration of 6TGR ex­
ceeded that of 6TG by a factor 1.5-3.0. This is in accordance with the 
findings in our study on 6MP in goats (Schouten et al 1985c). 6TGR (6-
thioguanosine) has been found to be equiactive to 6TG on a molar basis 
in humans when given by the intravenous route (Krakoff et al 1961). Thus 
the total biologically available amount of 6TG may be represented by the 
sum of the concentrations of 6TG and 6TGR (fig. 1 dotted lines). It can 
not be excluded, that the riboside concentrations exceeding the concen­
trations of the parent thiopurine is a typical phenomenon for goats. 
However we have also found considerable amounts of 6MPR in monkeys re­
ceiving 6MP (Schouten et al 1985b) and others have found 6TGR in plasma 
of humans after very high dose 30 minutes infusions (Konits et al 1982). 
In experiment В we could obtain a number of CSF samples from the lumbar 
space. The concentrations measured, are probably lower than the actual 
concentrations because of admixture of 0.9% NaCl solution used to flush 
the catheter. Therefore we have not depicted the concentrationtime curve 
of 6TG and 6TGR in CSF. Notwithstanding the admixture of 0.9% NaCl the 
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measured concentration of 6TG in CSF was ± 25% and of 6TGR ± 40% of the 
simultaneously obtained plasma concentration at the end of the infusion. 
The actually found penetration of 6TG into the CSF is in accordance with 
what one could expect on physicochemical grounds, like molecular size 
and partition coefficient in octanol-water (Mellett 1977). 
By providing a liberal and alkaline diuresis and extending the duration 
of infusion, we could prevent crystalluria and the ensuing risk of renal 
damage, which has been reported in humans (Konits et al 1982). Prolonged 
infusion of 6TG, resulting in steady state plasma concentrations for 
longer periods, may lead to a greater cell kill. In vitro studies by 
Wotring and Roti Roti have shown greater cell kill by 6TG at a concen­
tration of 10 vM during 12 hours than by 100 yM for 3 hours (Wotring and 
Roti Roti 1980). The 12 hour period equals the doubling time for the 
L1210 mouse leukaemic cells studied. One might infer that in humans the 
exposure time should be 24 hours or more, because the cell cycle of hu­
man cells is of that order. The administered dose in goats, 2 mg/kg/hour, 
resulted in a total concentration of 6TG and 6TGR of ± 10 μΜ, which is 
identical to the optimal concentration found by Wotring and Roti Roti 
during prolonged exposure (Wotring and Roti Roti 1980). 6TG and 6TGR are 
essentially S-phase specific drugs (Wotring and Roti Roti 1980, Lee and 
Sartorelli 1981). So one can predict that the activity of 6TG in slowly 
proliferating tumours is low, just as was found in patients with colo­
rectal carcinoma (Konits et al 1982, Britell et al 1981). In actively 
proliferating malignancies, e.g. acute leukaemia, 6TG is used extensi­
vely (Paterson and Tidd 1975). The absorption of 6TG after oral admini­
stration is variable (Brox et al 1981), and theoretically one could ex­
pect a better activity of 6TG after parenteral administration. It is our 
opinion that prolonged infusions of 6TG should be explored in humans. A 
dose of 2 mg/kg/hour, as we have used in goats, seems reasonable to 
start with. We advocate that pharmacological studies in humans should 
not only take into account 6TG concentrations, but also the metabolites 
of 6TG in plasma (Konits et al 1982). Moreover intracellular metaboli­
tes, preferably in the target cells, should be studied. For erythrocytes 
some data are available after 6MP administration (Lilleyman et al 1984). 
As has been found for 6MP and 6MPR (Schouten et al 1985c, Zimm et al 
1984), we also demonstrated the penetration of 6TG and 6TGR into CSF. 
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Therefore, if this penetration of 6TG into CSF is confirmed in humans, 
6TC may contribute in the prophylaxis and treatment of CNS leukaemia and 
in the treatment of brain tumours. 6TG may have some advantage over 6MP 
because a greater cell kill at a much lower, and in vivo probably easily 
attainable, concentration has been reported by Tidd and Paterson (Tidd 
and Paterson 1974). 
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CHAPTER Vili 
1.4 
6-MERCAPTOPURINE: HIGH-DOSE 24 HOURS INFUSIONS IN GOATS * 
2 
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John M. van Baal, Marinella В. van Leeuwen, Gerard A.M. de Vaan. 
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Center for Pediatric Oncology S.E. Netherlands, Department of 
Pediatrics, St. Radboud Hospital, Catholic University of Nijmegen, 
Nijmegen, The Netherlands. 
ABSTRACT 
In vitro investigations have pointed to the need of both a prolonged ex­
posure to 6-mercaptopuririe (6MP) and the use of high concentrations to 
archieve maximal cell kill. After the customary oral administration the 
bioavailability appeared to be low. I.v. bolus injections resulted in 
short-lived high concentrations of 6MP, so prolonged infusions seemed 
rational. To test the feasibility of this approach 24-hours infusions 
were given to goats. 
We used our improved HPLC method to quantitate 6MP and 6MP riboside 
(6MPR) in plasma, CSF and urine. The concentrations of 6MPR were in ex­
cess to those of 6MP. Since 6 MPR can easily be converted to 6MP, 6MPR 
acts as a depot for 6MP. Penetration of both 6MP and 6MPR into CSF was 
excellent. Of the total dose administered, 38% to 68% could be accounted 
for in the urine, with about equal amounts of 6MP and 6MPR. At doses of 
20 and 10 mg. kg . hr , total concentrations of 6MP and 6MPR in excess 
of 100 vM were reached during 24 hours infusions. However, all three 
experimental animals died due to toxicity. A dose of 2 mg. kg . hr 
was tolerable; the total steady state concentration of 6MP and 6MPR in 
two experiments was about 10 μΜ. 
We conclude that the prolonged infusion of 6MP is feasible and especial­
ly in view of the excellent penetration of 6MP and 6MPR into CSF, stu­
dies using prolonged infusions of 6MP are warranted in man. 
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INTRODUCTION 
For three decades the thiopurines, 6-mercaptopurine and 6-thioguanine, 
have been used in the treatment of malignant diseases, in particular the 
leukemias. The route of administration and the dose have been based on 
empirical grounds and clinical experience. 
The recent availability of sensitive and specific analytical methods has 
made it possible to perform sophisticated pharmacokinetic studies on 
these antimetabolites (1,2). The results of these studies led many in­
vestigators to question the rationale of the customary oral administra­
tion (3,4,26). 
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Metabolic activation of 6MP and 6TG is necessary in each individual 
target cell. This involves the transfer of ribose phosphate to 6MP or 
6TG with phosphoribosylpyrophosphate as a co-substrate and hypoxanthine 
guanine phosphoribosyl transferase as the enzyme. 6MP, an analog of hy­
poxanthine, is transformed to 6-thio-IMP, which can be further metabo­
lised to 6-thio-GMP by two rate-limiting key enzymes. On the other hand 
б-thio-IMP can be dephosphorylated to 6MPR by 5'-nucleotidase. 6TG, an 
analog of guanine, is transformed directly to 6-thio-GMP. Ultimately 
6-thio-GMP can be incorporated into DNA and RNA. 6-Thio-IMP and espe­
cially its methylated analog 6-methyl-thio-IMP have profound inhibitory 
effects on the purine de novo synthesis. Which of these biochemical 
pathways, either incorporation into DNA and RNA or blocking the purine 
de novo synthesis, is responsible for cell kill is still a point of dis­
cussion after so many years (7,14). It cannot be excluded that more than 
one mechanism is involved and that these mechanisms differ In various 
tumor (cell) models. Also the method by which a cytotoxic effect is mea­
sured may be of importance. For instance, growth inhibition may corre­
late with the well-known immunosuppressive effects of thiopurines. How­
ever, clonogenic assays are the methods of choice for assessing cyto­
toxic effects of anti-cancer drugs (9,16). In vitro studies, using clo­
nogenic assays, have pointed out the importance of the duration of expo­
sure, in addition to the effect of the concentrations of 6MP and 6TG 
(21,22,25). 
As a rule longer exposure and higher concentrations of 6MP or 6TG lead 
to greater cell kill. A plateau effect in cell kill becomes apparent at 
concentrations above 100-200 μΜ for 6MP and 1-2 yM for 6TG (23). 
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However, a recent study on 9L rat brain tumor cells continuously exposed 
to 6MP showed paradoxical behavior of 6MP as a cytotoxic agent i.e. de­
creasing cell kill with increasing drug dose (10). 
The in vitro data on thiopurines and the results of our recent and 
other pharmacokinetic studies (3,4,18,26) led us to suggest that pro­
longed infusions of thiopurines should be studied. By prolonged infusion 
both the problem of the erratic absorption after oral administration (3, 
4,26) and the limited period of measurable plasma concentrations after 
i.v. push injections (3,26) can be circumvented. 
Our data on children (18) and other data on monkeys (12) showed good pe­
netration of 6MP into cerebrospinal fluid. An earlier study by Nelson 
regarding this aspect was negative (13). On the other hand on physico-
chemical grounds, like molecular weight and lipid solubility, good pene­
tration of thiopurines into the CSF has been suggested by Mellett (11). 
Therefore it was also of interest to investigate to what extent thiopu­
rines reach the central nervous system during prolonged infusions. 
In the present paper we report on the feasibility of prolonged infusions 
of 6MP in goats, at different dose levels. 
MATERIALS AND METHODS 
Chemicals 
6MP was obtained from Burroughs Wellcome (London, England) and from 
Fluka (Hicol B.V., Rotterdam, The Netherlands). The 6MP solutions for 
i.v. infusions were prepared on the day of administration. Helium was 
flushed through all solutions in which 6MP was dissolved and diluted, 
in order to prevent oxidation of 6MP. The desired amount of 6MP was dis-
w 
solved in sodium bicarbonate 1.5% ( /ν), to which sodium hydroxide was 
added until 6MP was completely dissolved (final pH 9.6-10.2) (2). The 
ultimate concentration of the solution was dependent on the limited so­
lubility of 6MP, the dose to be administered, and the characteristics of 
the dual syringe infusion pump. 
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Experimental animals 
Goats were chosen as experimental animals, because CSF sampling from 
these animals had been performed previously in our Central Animal Labo­
ratory (8). Moreover, goats are rather docile, a prerequisite condition 
to maintain i.v. infusions for prolonged periods. During and after the 
experiments the goats were housed in the laboratory in separate stables. 
Initially catheters for i.v. infusion and for obtaining blood samples 
were placed percutaneously in both jugular veins on the day of the stu­
dy. Later on catheters were inserted by operation 4 to 5 days before the 
date of the infusion. To prevent catheter damage and to minimize the 
risk of systemic infection the catheters were tunnelled subcutaneously 
to the posterior neck. Heparine locks were used to preserve catheter pa­
tency. Care was taken to insert the catheter for infusion some 5 to 10 
cm deeper than the catheter for sampling purposes. 
On the day of the experiments attempts were made to insert a thin cathe­
ter by percutaneous puncture into the lumbar spinal canal. An indwelling 
balloon catheter was used for urine collection. 
The insertion of the various catheters was accomplished during a short 
thiopenthal and ketaraine narcosis. 
Dose and administration of 6MP 
In an initial experiment an i.v. push injection was given to obtain some 
basic pharmacokinetic parameters. In all other cases infusions were 
given which were planned to last 24 hours. The starting dose of 6MP was 
20 mg.kg .hour . The toxicity of the drug forced us to reduce the dose 
to 10 and 2 mg.kg .hour , respectively. We started with the higher 
dose, since our aim was to attain a concentration of 6MF in plasma in 
the order of 100-200 μΜ. The drug was infused by a dual syringe infusion 
pump. The pump was loaded with two 60 milliliter syringes. For practical 
reasons the volume per hour was chosen in such a way that syringes had 
to be changed either every four or every eight hours. The total amount 
of drug was prepared on the day of the experiment and stored in capped 
syringes at room temperature. The drug was infused through Millipore 
membrane filters, type Millex GS (pore size 0.22 pm). 
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Preparation of samples and 6MP determination 
Blood samples of 5-6 ml were collected in tubes containing heparin and 
300 \ig of DTT to prevent oxidation of 6MP (1,2). After thorough mixing, 
the blood was chilled and then centrifugad (5 min, 2000 χ g). One milli­
liter of plasma was transferred with a calibrated syringe into micro 
test-tubes (type 3810, Eppendorf, Hamburg, GFR) and kept on ice. Protein 
was precipitated by adding 0.1 ml recently prepared, ice-cold, trichlor­
oacetic acid (TCA) (50% /v) (2). After vigorous shaking, the tubes were 
kept on ice and after 10 minutes the precipitate was brought to sedimen­
tation by centrifugation (10 min, 2000 χ g). 
Cerebrospinal fluid samples of ± 0.5 ml were taken and put in micro 
test-tubes containing DTT. 
Urine samples were taken from measured aliquots collected during speci­
fied time periods. Before samples were taken care was given to dissolve 
deposits in the collecting reservoirs. Urine samples were put in tubes 
containing DTT. Before analysis NaOH was added to dissolve any deposit. 
6MP and 6MPR concentrations were determined on a Spectra Physics SP 8000 
high performance liquid Chromatograph as previously described (2). The 
concentrations of 6MP and 6MPR are expressed in μΜ. 
RESULTS 
The concentration-time profile after bolus injection of 6MP, in a dose 
of 20 mg.kg (total dose 260 mg = 1.71 mmol) is depicted in Chart 1. 
Chart 1 illustrates a new and interesting point i.e. the presence of the 
riboside of 6MP in fairly high concentrations in plasma as well as in 
CSF. The 6MPR concentrations both in plasma and CSF are even far in 
excess of concentrations of 6MP itself. In an addendum the data are 
fitted by pharmacokinetic modeling. 
The second experiment, intended to be a 24 hours infusion (dose 20 mg. 
kg . hour ), had to be stopped after 2 hours of infusion, because 
of excessive stress to the goat from the experimental procedures. Al­
though the experiment could not be completed as planned, the data are of 
interest (Chart 2). After breaking off the infusion, the 6MP concentra­
tion in plasma declined rapidly, but the 6MPR concentrations declined 
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Chart 1. Concentration-time curve after an i.v. bolus injection of 6MP 
(total dose 260 mg = 1.71 mmol). 
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Chart 2. Concentration-time curve during and after a 2 hours infusion of 
6MP (total dose 832 mg » 5.46 mmol). 
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slowly. Penetration of 6MP and 6MPR into the CSF is excellent. The con­
centration of 6MP in CSF remains rather high and exceeds 6MP concentra­
tions in plasma within half an hour after stopping the infusion of 6MP. 
In these first two experiments it appeared that the percutaneous intro­
duction of a catheter into the lumbar space is difficult and resulted in 
paralysis of the hind legs of the goats. To limit the discomfort to the 
animals no further attempts were undertaken to sample CSF during 24 
hours infusions. 
In the third experiment, at a dose level of 20 mg.kg .hour , the im­
portance of forced diuresis became apparent; after 6-8 hours of infusion 
anuria developed due to crystalluria. At the same moment the 6MP concen­
tration in plasma became higher than the 6MPR concentration. This sug­
gests that renal excretion is a major factor in the clearance of 6MP du­
ring long-term infusions (Chart 3). Therefore in the following experi­
ments liberal amounts of intravenous fluids (100-150 ml.kg .day ) were 
given and urine pH was kept above 7.0 by intermittent i.v. administra­
tion of sodium bicarbonate (8.2%). 
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Chart 3. Concentration-time curve during and after a 21 hours infusion 
of 6MP (total dose 7,000 mg = 45.53 mmol). 
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With a dose of 10 mg. kg .hour two very similar concentration-time 
profiles regarding 6MP and 6MPR concentrations in plasma were obtained. 
(Chart 4 shows one of them). Unfortunately the goats did not survive for 
longer than 48 and 96 hours respectively after stopping the infusions. 
Both goats had shown ill health and severe leucopenia shortly before dy-
ing, so a fulminant infection is possible. Routine clinical chemistry 
showed a tendency to increased values of urea, creatinine and liver 
transaminases. At autopsy the internal organs were macroscopically unre-
markable. 
In the last two experiments, with a dose of 2 mg.kg .hr , the feasibi-
lity of 24 hours infusion of 6MP was demonstrated (Chart 5). Both goats 
ultimately survived in good health, although abscesses around the tun-
nelled catheters appeared in both of them. On conservative management 
these abscesses cleared. Haematological toxicity was absent, however 
transient hepatic damage became evident 5-10 days after exposure to 6MP. 
Values of liver transaminases rose to levels 3-6 times above the pre-
treatment levels and then returned to normal within a 3 weeks observa-
tion period. 
The maintenance of properly functioning bladder catheters was difficult 
because of expression of the catheter by the goat. Sometimes there was 
loss of urine along the catheter. Furthermore crystalluria occurred at 
higher dose levels. Therefore incomplete data on the urine excretion are 
available. After the i.v. push injection 68.5% of the dose administered 
was recovered from the urine: 36% as 6MP and 32% as 6MPR. 
In one of the two goats receiving 6MP in a dose of 10 mg.kg . hour 
43% of the total dose administered during 24 hours, could be accounted 
for in the urine, with about equimolar amounts of 6MP and 6MPR. This is 
the minimum amount excreted because some urine was lost and also crys-
tals were present in the collecting reservoir. 
In the two experiments with a dose of 2 mg.kg .hr combined urinary 
excretion of 6MP and 6MPR was 38% and 63% of the total dose. After stop-
ping the infusion of 6MP, the excretion in urine declined very rapidly, 
so 6MP and 6MPR were hardly detectable 4-6 hours after stopping the ad-
ministration of 6MP. 
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Chart 4. Concentration-time curve during and after a 24 hours infusion 
of 6MP (total dose 4,080 mg • 23.97 mmol). 
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Chart 5. Concentration-time curve during and after a 24 hours infusion 
of 6MP (total dose 1,008 mg = 5.92 mmol). 
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DISCUSSION 
In the present study we have shown that 24 hours infusions are feasible 
without undue toxicity at a dose level of 2 mg.kg .hour 
So the in vitro optimal way of exposure to 6MP (23) can be simulated in 
vivo by prolonged i.v. infusions. 
In this study on goats a metabolite of 6MP, I.e. the riboside of 6MP, 
was present in high concentrations both absolute and relative to 6MP. 
6MPR can only be converted to 6MP, so 6MPR can be regarded as a kind of 
prodrug of 6MP. In the past it has been demonstrated that on molar ba­
sis both substances, 6MP and 6MPR, are equitoxic (15). Therefore the 
biological activity may better be represented by the sum of the molar 
concentrations of 6MP and 6MPR. 
From charts 3, 4 and 5 it can be seen that steady state concentrations 
of 6MP are attained in 1-2 hours. 6MP concentrations in plasma remain 
constant as long as the infusions are maintained (Chart 4 and 5), pro­
vided that crystalluria is prevented by forced and alkaline diuresis 
(Chart 3). 
A steady state concentration for 6MPR is also reached after about 2 
hours. At a dose level of 10 mg.kg .hour , there is a tendency to 
an Increase in 6MPR concentration with time (Chart 4). This is not 
apparent at a dose level of 2 mg.kg .hour (Chart 5). 
The sum of the concentrations of 6MP and 6MPR at a dose rate of 20 mg. 
kg" .hour" is in a range of 200-300 μΜ (Chart 2 and 3). This is probab­
ly so high partially because no extra fluids were given in these two ex­
periments. With forced diuresis a combined concentration of 95 μΜ was 
attained after 4 hours during a 6 hours infusion at 20 mg.kg hour 
Catheter breakdown precluded further study, but this goat did survive in 
good health (data not shown). At a dose rate of 10 mg.kg . hour the 
concentration of 6MP plus 6MPR was lower at about 60 μΜ (Chart 4), un­
fortunately both goats succumbed to severe myelotoxicity. Both goats, 
receiving a dose of 2 mg.kg .hour during 24 hours, did survive. The 
combined concentration of 6MP and 6MPR was slightly above 10 μΜ during 
the infusion. This concentration in vivo is much lower than the in vitro 
maximal effective concentration of 100-200 μΜ as reported by Tidd and 
Paterson for L5178Y mouse lymphoma cells (23). However, actual measured 
steady state concentrations of 6MP during continuous infusion may not be 
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compared directly to the concentrations present in vitro at the start of 
a prolonged incubation period. In our laboratory in vitro experiments on 
MOLT-4 human leukemic cells with a starting concentration of 2 μΜ 6MP, 
pointed out that most of the drug has disappeared from the medium within 
3 hours, hence far before the end of a 24 hours incubation period 
Moreover, for 6MP the general rule "the higher the dose, the greater the 
effect", is not necessarily true (10). 
We demonstrated that 6MP and 6MPR penetrate well into the CSF (Chart 1 
and 2). This provides further evidence that 6MP might be of interest in 
the treatment of brain tumors and the prevention of meningeal leukemia. 
Our findings in this and in our earlier study (18), and data in the 
literature (12) contradict earlier negative findings on the penetration 
of 6MP and 6MPR into the CSF (13). 
Collection of urine from goats during prolonged periods of time is cum­
bersome. Moreover the metabolism of uric acid as well as of thiouric 
acid in these animals is different from that in man. Therefore our data 
on urinary excretion can be regarded as exploratory only. Anyhow a major 
proportion of the total dose administered was recovered from the urine 
either as 6MP or 6MPR. 
We did not try to define more precisely a maximally tolerated dose per 
hour during 24 hours infusions in goats. Eventually this has to be done 
in man using an escalating dose schedule. 
A number of problems can be predicted when this kind of administration 
is applied to man in future studies. The poor solubility of 6MP poses 
pharmaceutical problems, which probably can be solved by selecting more 
soluble analogs like 6MPR. The same problem and solution might pertain 
to 6TG, which in vitro is more potent than 6MP (23). 
6MP and catabolites are poorly soluble in urine so a forced diuresis of 
alkaline urine is a prerequisite condition for the administration of 
high doses of 6MP, as we learned in this study and as already could be 
concluded from observations in man (5). 6MP is easily oxidized in biolo­
gical fluids (1), so urine should be collected in reservoirs containing 
an anti-oxidant like DTT, when the excretion profile is studied. If ne­
cessary, crystals in stored samples of urine can be redissolved by in­
creasing the pH before analysis. 
The concentration of 6MP plus 6MPR, about 10 μΜ at a dose level of 2 mg. 
kg .hour , is in the range of the concentration of hypoxanthine and 
98 
inosine in bone marrow "juice" and CSF (6,20). Hypoxanthlne and 6MP are 
both substrates for the same activating enzyme hypoxanthlne guanine 
phosphoribosyl transferase, with IMP and 6-thio-IMP, respectively as the 
products. So it is conceivable that physiological variations in hypoxan-
thlne concentrations can influence the effectivity of 6MP. In this way 
normal bone marrow cells can be protected against the toxic effects of 
6MP, but in the case of leukemia the leukemic cells may escape desired 
cytotoxicity. 
Another important problem to circumvent is the relatively high rate of 
natural and easily acquired resistance of malignant cells to 6MP and 
6TG. This is either due to lack of the enzyme hypoxanthlne guanine phos-
phoribosyl transferase or to elevated levels of alkaline phosphatase 
(17,19). So the thiopurines should be combined with other cytostatic 
drugs. 
The excellent penetration of 6MP and 6MPR into CSF justifies phase I and 
phase II studies on high dose prolonged l.v. infusions of thiopurines in 
man. 
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ADDENDUM 
The data obtained in the experiment depicted in Chart 1 were fitted by 
non-linear least squares by means of NONLIN according to the reversible 
metabolic model: 
kme 
This resulted in the following parameters: 
rameter 
kpm 
kpe 
kmp 
kme 
Vp 
estimate 
3.279 
2.607 
0.532 
0.993 
8.73 
s.d. 
0.819 
1.416 
0.149 
0.183 
2.6 
L-l 
s.e. = 0.079 with 23 degrees of freedom. 
2 
weighting 1/c 
t, intrinsic parent drug : 7 min. 
t, intrinsic metabolite : 27 min. H 
t, elimination-phase 42 min. 
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abbreviations: 
Ρ = parent drug 6MP 
M = metabolite 6MPR 
kpm = rate constant of metabolism from Ρ to M in h 
kmp = rate constant of metabolism from M to Ρ in h 
kpe = rate constant of total clearance of Ρ in h 
krae » rate constant of total clearance of M in h 
Vp = distribution volume of Ρ in 1 
с " concentration 
s.d. = standard deviation 
s.e. = standard error 
The equation (t, elimination-phase observed = —£ )shows that the 
t1 elimination-phase is governed by the total clearance of the metabo-
lite. The clearance of the metabolite is probably mainly renal, so pa-
tients with an impaired renal function are prone to a decreased clea-
rance of the metabolite, resulting in a prolongation of t, elimination-
phase and increased toxicity of parent drug and metabolite. 
NONLIN according to: Metzler CM, Elfring GL, McEwen AJ. 
A package of computer programs for pharmacokinetic modeling. 
Biometrics 1974;30:562. 
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CHAPTER IX 
6-MERCAPTOPURINE AND 6-THIOGUANINE: SURVEY AND SUMMARY 
6MP AND 6TG AS ANTILEUKAEMIC AGENTS AND THE AIM OF OUR INVESTIGATIONS 
6-Mercaptopurine and 6-thIoguanine are mainly and extensively used in 
the maintenance treatment of ALL and AML. These drugs have been used for 
decades now and both the dose and way of administration, i.e. daily low 
doses orally, have hardly changed in this period of time (1, 2, 3, 4, 5, 
6). In the sixties the treatment of ALL of childhood was divided into 
two phases, i.e. the induction and the maintenance treatment. The third 
phase, which is included at present, is the so-called CNS prophylaxis. 
This phase is usually spaced between induction and maintenance treatment 
(5, 6). 
In the maintenance treatment of childhood ALL 6MP is the mainstay. The 
drug is given in a dose of 50-90 mg/m2, once daily by the oral route, in 
combination with methotrexate, which is administered once weekly in a 
dose of 20-30 mg/m2 orally or eventually by the parenteral route (5, 6). 
However it should be marked that in 1980 Frei (7), one of the pioneers 
of maintenance therapy in childhood ALL, rejected the concept of mainte-
nance chemotherapy. Maintenance therapy for leukaemia and lymphomas has 
been demonstrated to prolong the duration of remission, but there is no 
clear evidence from any study that maintenance treatment, delivered at 
low doses, will increase the cure rate. Indeed, the original goal of 
maintenance treatment was prolonging the time until relapse, and not 
increasing the cure rate (7). 
In vitro studies on 6MP reported in the seventies by Tidd and Paterson 
made us aware of the importance of high concentrations of the drug du-
ring prolonged periods of exposure (8, 9, 10). Their in vitro studies 
prompted Wotring and Roti Roti to emphasize the importance of extended 
exposure to 6TG (11). This latter study and also other investigations 
made clear the S-phase specific cytotoxic activity of 6MP and 6TG (12, 
13). Park and coworkers and Lihou and Smith testing the chemosensitivi-
ty of human leukaemic cells recently emphasized the importance of pro-
longed exposure to S-phase specific agents (14, 15). 
The original aim of our studies was to gain insight into the clinical 
pharmacology and pharmacokinetics of 6MP, as applied in the maintenance 
treatment of childhood ALL. The first results of our studies in man and 
dogs learned us that we should take a fresh look on 6MP and also on 6TG. 
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Both drugs are vintage anticancer drugs and used extensively in the 
maintenance treatment of ALL and AML. The dose, way and schedule of ad-
ministration of 6MP and 6TG however are based on empirism and not on 
sound experimental grounds. In exploring other dosages, routes and sche-
dules of administration of 6MP and 6TG we made a start in providing such 
an experimental basis. 
In the following paragraphs we discuss our studies on 6MP and 6TG. We 
will present a short survey on recent studies on the clinical pharmaco-
logy and pharmacokinetics of 6MP and 6TG. 
6MP AND 6TG: SURVEY OF OUR STUDIES 
Development of sensitive and specific methods to determine 6MP, 6TG, 6MPR 
and 6TGR 
As a first objective we developed a method to determine 6MP in clinical-
ly relevant concentrations. An HPLC method was devised which was speci-
fic and sensitive. A major step was the use of DTT (dithiothreïtol) as a 
protective agent throughout the whole analytical procedure. By this step 
the recovery of 6MP increased from 20% to 94%. Also a relatively large 
injection volume of 460 ul was used to reduce the limit of detection. We 
were able to measure concentrations as low as 3 ng/ml, equivalent to 16 
nmol/liter or 0.016 yM. The time necessary to perform an analysis was 
relatively short: in the order of 20-30 minutes per sample (Chapter II). 
In the latter part of the study we were interested in 6TG, so we adapted 
our previous HPLC method in such a way that also 6TG and the ribosides 
of both 6MP and 6TG could be measured by the same analytical procedure. 
The HPLC columns were prepared and packed in our own laboratory and two 
columns were used in series. Advantage was taken of the presence of two 
u.v. detectors and a dual-channel printer-plotter in the HPLC-apparatus. 
6MP and 6MPR were monitored at 312 nm, and 6TG and 6TGR at 342 nm. These 
wavelengths are close to the absorbance maximum of these substances. The 
relative absorbances at two different wavelengths are of help in charac-
terizing the various peaks. The lower limit of detection was for 6MP 
found to be at 20 nM, for 6TG at 25 nM, for 6MPR at 65 nM and for 6TGR 
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at 60 nM. It is possible to apply different injection volumes, depending 
on whether a 190 or 500 μΐ injection loop is used. A smaller injection 
volume gives less deterioration of the HPLC column, while with a larger 
loop a lower limit of detection is possible. The protective agent, DTT, 
is of course also used in this new adapted method and degassing of all 
solutions by helium was also applied again. 
Explorative pharmacokinetic studies in ALL patients and dogs 
In an orientating study on patients (Chapter IV), receiving maintenance 
treatment according to the operative protocol V of the "Stichting Neder­
landse Werkgroep Leukemie bij Kinderen" (SNWLK), plasma and CSF concen­
trations of 6MP were determined. The HPLC method described in chapter II 
was applied. Samples were obtained on the occasion of vena punctures and 
lumbar punctures scheduled as required by the protocol. All samples were 
taken about 24 hours after the last of 35 daily doses of 6MP orally. The 
mean plasma concentration was 0.064 yM. Establishing the presence of 6MP 
in CSF, with a mean concentration of 0.029 μΜ, was somewhat surprising 
because earlier studies could not prove such a penetration of 6MP into 
CSF (16, 17). The ratio of the mean 6MP concentration in CSF to the mean 
6MP concentration in plasma was approximately 0.40. We could not compare 
oral vs. intravenous administration, as 6MP suitable for i.v. application 
to humans was not available to us. Concentration-time curves of 6MP af­
ter oral administration in the standard dose of 50 mg/m2 were therefore 
not obtained. 
In parallel with our orientating study in patients with ALL, we started 
an explorative study in dogs (Chapter V). We applied 6MP of analytical 
grade for intravenous administration in animals. We could also study 
some pharmacological aspects of oral administration. A concentration-
time curve after a first oral dose of 6MP, as a 50 mg commercially avai­
lable tablet, revealed a low and late appearing peak of 6MP in plasma. 
This peak concentration was rather low, 0.040 yM, while concentrations 
in a range of 20-200 yM are necessary to obtain a cytotoxic effect in 
vitro (8). On the other hand daily administration of 6MP by the oral 
route at an usual clinical dose resulted in "steady state" levels of 6MP 
in plasma after 2-3 weeks. After 10 days of application of 6MP in the 
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same dose by the i.v. route this was not observed. Rather peculiar was 
the observation of the persistence of these "steady state" levels after 
oral administration with a mean of 0.150 μΜ, during 3-6 weeks after 
stopping the administration of 6MP. A similar phenomenon has been 
observed in children off maintenance treatment for ALL after 2 years of 
continuous complete remission. The persistence of 6MP in plasma of dogs 
for weeks after discontinuation of 6MP implicates a kind of deposit of 
the drug. Tight binding of 6MP to plasma and/or liver proteins may play 
a role. Worth mentioning is the presence of thioguanine nucleotides in 
erythrocytes of patients with ALL during maintenance treatment (18). 
Concentration-time curves in dogs after the usual clinical dose of 50 mg 
i.v. revealed peak plasma concentrations with a range of 2.5-10.5 yM. 
The concentrations of 6MP declined rapidly to less than 0.10 μΜ. This is 
reflected by a short first half-life time of 13-21 minutes. The second 
half-life time had a range of 125-151 minutes. 
From our first explorative pharmacokinetic studies (Chapter IV and V) we 
realized that the customary low-dose oral administration of 6MP and 6TG 
was founded only on empirlsm and had no experimental basis. Our first 
results gave the direction for further investigations. The finding of 
the presence of 6MP in CSF, albeit in very low concentrations, encouraged 
us to continue our study with regard to this aspect. The low 6MP plasma 
concentrations which we found after the customary dose, either after 
oral or i.v. bolus administration, brought us to study much higher doses 
and to explore parenteral administration by prolonged i.v. infusions. 
This departure from the customary dose and route of administration of 
6MP, and 6TG, was sustained by an article of Frei and Canellos (7). 
These authors drew attention to the critical role of dose in cancer che­
motherapy and rejected the concept of maintenance therapy as part of cu­
rative intended chemotherapy of disseminated malignant disease. 
Infusions of 6MP and 6TG in monkeys and goats 
In our experiments on marmoset monkeys we made the step to infusions of 
6MP (Chapter VI). Since technical and practical reasons precluded infu­
sion durations of more than a few hours, a one- and a four-hours infu-
Г 14 1 
sion was given with 18- С -6MP. Following the insights gained in our 
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studies so far, a high dose rate of 5 mg/kg/hour was used. This resulted 
in steady state levels in plasma in the range of 30-40 μΜ within half an 
hour after the start of the infusion. 6MPR could be detected shortly af­
ter starting the infusion; the 6MPR level attained was 20-35% of the 6MP 
concentration during the infusion period. After termination of the infu­
sion 6MP and 6MPR concentrations got equal, 6MPR, which is formed from 
6MP intracellularly by phosphoribosylation and subsequent dephosphoryla-
tion, can only be degraded to 6MP. So 6MPR acts as a kind of depot form 
for 6MP. 
Γ 14 1 
In order to obtain autoradiograms of the animals 18- CI-6MP was used. 
Γ Η 1 L J 
After infusion of 8- С -6MP a two-hours period was observed before 
the animals were sacrificed. The autoradiograms revealed extensive dis­
tribution of the radiolabel throughout the body. Intense activity was 
present in liver, gall bladder and intestinal lumen. Other points of in­
terest are the apparent penetration of the label into the central ner­
vous system and the accumulation of activity within the bone marrow. In 
patients with leukaemia the bulk of the malignant cells resides in the 
bone marrow, so 6MP should preferably be active at this site of the 
body. However, the forms in which the label is present at the various 
sites are not known. We are aware of the fact that in plasma four la­
beled substances (6MP, 6MPR, 6TX, 6TU) are present, and in concentra­
tions variable over time. Ideally, in further studies one should try to 
correlate intracellular and intravascular concentrations of 6MP, 6MPR 
and other metabolites to gain a more thorough understanding of the 
pharmacological and metabolical fate of 6MP and its derivatives. 
In Chapter VII and VIII, we made use of our adapted method for determi­
nation of 6MP, 6MPR, 6TG and 6TGR (Chapter III). We had extended our 
original interest in 6MP as used in maintenance treatment and included 
the closely related drug 6TG. The arguments for this have been presented 
in Chapter I. In summary, 6TG might have advantages over 6MP, as the 
maximal cytotoxic effect was demonstrated to be somewhat greater for 6TG 
as compared with 6MP (10). The concentrations of 6TG necessary in vitro 
to attain a maximal cell kill (1-2 μΜ) are more likely to be applicable 
in vivo than the concentrations of 6MP which are necessary for an analo­
gous effect (100-200 μΜ) (10). Moreover, 6TG has a more direct metabolic 
pathway to the site of the cytotoxic effect, viz. incorporation into DNA 
as 6-thio-dGTP. 
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In Chapter VII the results of three experiments in goats, using two-hours 
infusions of 6TG, are presented. A dose of 2 mg/kg/hour was chosen and 
this dose quickly resulted in a mean steady state level of 6TG of about 
3 μΜ. 6TGR was even present in concentrations exceeding those of 6TG 
itself. Although 6TGR is formed intracellularly from 6TG by the addition 
of a phosphoribosyl group and subsequent dephosphorylation, 6TGR can 
only be converted back to 6TG by an enzymatic process involving purine 
nucleoside Phosphorylase. Therefore 6TGR can also be regarded as a kind 
of depot or prodrug for 6TG. The total biological activity of 6TG and 
6TGR may be represented by the sum of their concentrations, which is 
about 10 μΜ during the second hour of the infusion. This concentration 
is of the same order as the concentrations which were found to exert a 
good cytotoxic effect in vitro (10, 11). However, because of the limited 
duration of the infusions studied, these concentrations were not 
sustained for as long as is necessary in vitro (11). 
In one experiment we obtained several samples of CSF. The concentration 
of 6TG found in CSF was about 25% of simultaneously measured plasma 6TG. 
The penetration for 6TGR was even better; in CSF 40% of the simulta­
neously obtained plasma concentration was present. On physicochemical 
grounds reviewed by Mellet in 1977 one would expect 6TG to reach the CSF 
(19), although this was not found in dogs by Loo and coworkers (20). If 
this penetration of 6TG and 6TGR into CSF is confirmed in humans, these 
drugs may contribute to the prophylaxis and treatment of CNS leukaemia 
and to the treatment of brain tumours. 
Urinary excretion of 6TG and 6TGR was found during and immediately after 
the infusion of 6TG. After 4 hours only negligible amounts of 6TG and 
6TGR were observed. The combined amounts of 6TG and 6TGR recovered from 
urine varied from 26 to 49% of the amount of 6TG administered. Catabo-
lites of 6TG were not determined, but it is likely that most of the 
drug, either in active or inactive form, is excreted quickly. A liberal 
diuresis is necessary to prevent crystallurla and renal damage, which 
has been observed in humans (21). 
We observed this problem of crystallurla and renal damage also in our 
studies in goats, using prolonged, i.e. 24-hours infusions of 6MP (Chap­
ter VIII). We started at a really high dose of 6MP, 20 mg/kg/hour, in an 
attempt to attain and maintain concentrations in plasma in the order of 
100-200 μΜ. These latter concentrations of 6MP must be present in vitro 
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to obtain a maximal cell killing effect (10). Indeed concentrations in 
that order, 6MP combined with 6MPR, were demonstrated at dose levels of 
10 and 20 mg/kg/hour. The riboside of the parent drug, 6MPR, was again 
found to be present in amounts far exceeding those of 6MP itself. In the 
past 6MP and 6MPR have been demonstrated to be equitoxic on a molar ba­
sis. So again, as for 6TG and 6TGR, the total biologically active amount 
of drug may be best represented by the sum of the molar concentrations 
of 6MP and 6MPR. Acute renal toxicity due to crystalluria, because of 
the poor solubility of 6MP and its metabolites, could be handled by 
providing a liberal and alkaline diuresis. However, at a dose rate of 10 
mg/kg/hour, severe myelotoxicity became evident. This forced us to redu­
ce the dose rate. A dose rate of 2 mg/kg/hour during 24 hours seemed 
feasible; no important permanent toxicity was observed. Under these 
experimental conditions a combined steady state plasma concentration of 
6MP and 6MPR was found in the order of 10 μΜ. 
Worth mentioning is the observed excellent penetration of both 6MP and 
6MPR into CSF. After a bolus injection of 6MP in a dose of 20 mg/kg con­
centration-time curves of 6MP and 6MPR in plasma as well as in lumbar 
CSF could be made. In a two-hours infusion at a dose rate of 20 
mg/kg/hour these findings were confirmed and extended. 
6MP: EVALUATION OF RECENT PHARMACOLOGICAL AND PHARMACOKINETIC STUDIES 
FROM THE LITERATURE 
The renewed interest in studies on 6MP and 6TG is evident from an 
increasing number of published methods to quantitate these substances. 
High-performance liquid chromatography is successfully applied to 
analyze 6MP, 6TG and metabolites. 
In this review we will limit us to the discussion of the recent studies 
using HPLC methods to determine 6MP and 6TG. For earlier studies one may 
be referred to the reviews by Paterson and Tidd (1975), LePage (1977), 
and McCormack (1982) (1, 2, 3). 
A new era of pharmacokinetic studies on the thiopurines was started by 
Ding and Benet in 1979 (22). These studies were extended by a group at 
the National Cancer Institute, Bethesda, U.S.A. (23, 24, 25, 26). The 
study by Ding and Benet revealed that on an average only 12% of the oral 
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6MP dose was available to the systemic circulation in rhesus monkeys. A 
solution of 6MP was given through surgically implanted stomach tubes and 
not as a tablet or powder per os as is clinically done. By giving 6MP as 
an oral solution, dissolution problems are eliminated. The low bioavai­
lability of 6MP in the rhesus monkeys may be caused by a combination of 
poor absorption and metabolism by xanthine oxidase in the small intes­
tine and in the liver. Using a two-compartment open model a th, 1 from 
2.7 to 11.2 minutes was found in 4 monkeys. The mean th, 2 was 41.6 
(range 24.2-51.7) minutes. Concentrations of 6MP in plasma three hours 
after a bolus injection were about 1% of peak plasma concentrations 
(22). 
In a study, by Narang and coworkers, on the pharmacokinetics of 6MP in 
the monkey excellent penetration of 6MP into the CSF was showed (23). In 
three monkeys concentration-time curves of 6MP were obtained simulta­
neously in plasma and CSF, after an i.v. bolus injection of 4 mg/kg. The 
mean peak concentration in CSF was about 3 μΜ and was observed approxi­
mately 40 minutes after i.v. bolus injection. The decline of drug con­
centration in the CSF almost paralleled the plasma concentration decline 
and appears to suggest the concentration gradient of the plasma compart­
ment to be the driving force behind the partitioning of 6MP between 
plasma and CSF. The ratio of 6MP concentration in CSF over that in plas­
ma in the three monkeys varied between 0.4 and 1.0. The plasma concen­
tration-time curves could be fitted into a three-compartment open model, 
in contrast co the two-compartment model used by Ding and Benet (22). In 
our studies on dogs we could fit our data best into a two-compartment 
open model (Chapter V). 
Further investigations by the same team of investigators from the NCI 
involved the bioavailability of 6MP in monkeys and in man (24, 25). In 
monkeys, using doses of 8 mg/kg, equivalent to 100 mg/га2, there was a 
marked difference in AUG (area under curve) between the oral and intra­
venous plasma concentration-time curves, indicating a bioavailability of 
oral 6MP of 4 per cent (24). In patients, receiving maintenance treat­
ment for ALL, there was also a substantial difference in AUG after oral 
and intravenous administration, indicating a mean bioavailability of 
oral mercaptopurine of only 16 per cent (range 5 to 37 per cent). The 
mean peak plasma concentration of 6MP, after an oral dose of 75 mg/m2, 
in 14 fasting children was 0.89 μΜ (range, 0.29 to 1.82), with a mean 
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time to peak concentration of 2.2 hours (range, 0.5 to 4). Under normal 
circumstances, the presence of food in the stomach may act as an 
additional source of variability (24). 
In another report by Zimm and coworkers, the reason for the low bioavai­
lability of 6MP after oral administration was explored (25). Ding and 
Benet, and Zimm and coworkers had already suggested the first-pass ef­
fect to be the cause for the low bioavailability of 6MP (22, 24). The 
first-pass effect refers to the presystemic metabolism of oral drugs by 
liver or gut mucosal enzymes. For 6MP the catabolizing enzyme xanthine 
oxidase is involved and located primarily in intestinal mucosa and li­
ver. By using allopurinol, a well-known inhibitor of xanthine oxidase, 
the bioavailability in man increased from a mean of 12 to a mean of 59 
per cent (25). Allopurinol had no effect on the pharmacokinetics of 
intravenously administered 6MP. However, allopurinol may deplete intra­
cellular PRPP pools and increase hypoxanthine levels. Both changes may 
diminish 6MP antileukaemic activity (25). The metabolic effects of allo­
purinol and the interaction with 6MP are species specific, as was demon­
strated by investigations on the pharmacokinetics of 6MP in rabbits 
(27). 
The last study on 6MP to be discussed here, is reported by Zimm and co­
workers in abstract only (26). In this preliminary report prolonged in­
travenous infusions of 6MP during 12-24 hours at a dose rate of 50 mg/ 
m
2/hour are described. Obviously Zimm and coworkers followed the same 
line of reasoning as we did (Chapter I). The mean steady-state plasma 
concentration achieved in 9 patients was 6.2 yM, with a less than two­
fold difference between the highest and lowest plasma concentrations. 
In four patients CSF samples were obtained six or more hours after the 
start of the infusion. The mean CSF level of 6MP at steady-state was 1.9 
μΜ and the mean CSF/plasma ratio for 6MP was 0.39. This latter ratio is 
nearly identical to the ratio we have found during conventional mainte­
nance treatment for ALL (Chapter IV). The dose rate of 50 mg/m2/hour is 
also nearly identical to the dose rate we have found to be feasible in 
goats (Chapter VIII). 
In the studies discussed in this paragraph the presence of 6MPR in plas­
ma or CSF is not mentioned. However, we have demonstrated even higher 
concentrations of 6MPR than of 6MP itself in plasma and CSF from goats 
(Chapter VIII). Also 6MPR was found to be present in plasma of marmoset 
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monkeys in fair concentrations, as compared to 6MP concentrations 
(Chapter VII). Whether 6MPR was not present in plasma of rhesus monkeys 
or ALL patients studied by Zimra and coworkers, or was not determined 
because of limitations in their analytical procedure, is not clear to 
us. Preliminary data from children, using our improved method of ana­
lysis, has demonstrated the presence of 6MPR in plasma and CSF, after 
administration of 6MP as well as after administration of 6TG. 
6TG: EVALUATION OF RECENT PHARMACOLOGICAL AND PHARMACOKINETIC STUDIES 
FROM THE LITERATURE 
The first pharmacological study in which HPLC was used for analysis of 
6TG in plasma was reported in 1981 (28). Brox and coworkers state that 
only one other pharmacological study had been reported earlier. This 
report by LePage and Whitecar, published in 1971, already drew attention 
to the very low concentrations of 6TG in plasma after oral adminis­
tration compared to i.v. dosing (29). The study by Brox and coworkers 
disclosed a 30-fold range in peak plasma concentration, i.e. from 0.03 
to 0.94 μΜ, after oral 6TG in fasting patients with AML. They correlated 
the peak plasma concentrations observed in patients to the in vitro con­
centration of 6TG, i.e. 0.5 yM, required for both complete inhibition of 
cell growth and cell lysis during continuous exposure. In only 4 out of 
25 6TG courses the peak plasma level of 6TG exceeded 0.5 μΜ and that 
only for a short period of time. Their study illustrates the erratic 
oral absorption of 6TG and the frequently low peak plasma levels. Brox 
and coworkers suggest that the i.v. formulation of 6TG may be superior 
to the oral gift of the same drug. 
In a study, reported by Konits et al in 1982, 6TG was actually given 
i.v. in high dosage by 30 minutes infusions to patients with colorectal 
carcinoma (21). Doses of 6TG, ranging from 1000 to 1200 mg/m2 resulted 
in peak plasma concentrations of 61 to 118 μΜ, with an initial t*s of 3 
hours and a terminal t^ of 5.9 hours. A number of known and other, as 
yet unidentified, metabolites were found in plasma. In humans 6TGR was 
demonstrated, although in relatively low concentration in comparison 
with the values we observed in goats (Chapter VII). Crystals of 6TG and 
6TU were observed In the urine of all six patients from whom urine was 
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collected. The solubility of 6TG and 6TU is poor, and it seems plausible 
that 6TG and 6TU may precipitate in the renal parenchyma. The finding of 
renal toxicity, reflected by increases in serum creatinine, in 4 out of 
19 patients studied, is in our opinion related to the crystalluria ob­
served by the authors (21). 
6MP AND 6TG: A FRESH LOOK ON THEIR APPLICATION 
Our study and data from the literature, summarized above, have made it 
clear that the oral administration of 6MP results in a low bioavailabi­
lity (22, 24, 25) and that the absorption of 6TG is erratic (28). These 
findings prompted us to explore other dosages and ways of administra­
tion. We demonstrated the feasibility of administering 6MP at a dose 
rate of 2 mg/kg/hour by 24 hours infusions in goats. In preliminary 
form similar findings have been presented on patients with ALL (26). The 
dose rate used in these two investigations, 2 mg/kg/hour and 50 mg/m2/ 
hour respectively, was similar. In both reports excellent penetration of 
6MP into the CSF was established. While we have found higher concen­
trations of 6MPR than of 6MP itself in plasma and CSF from goats, the 
presence of 6MPR is not mentioned by Zimm and coworkers (26). It is li­
kely they did not quantitate 6MPR because of limitations in their method 
of analysis. We observed 6MPR to be present in plasma from marmoset mon­
keys at 20 to 35% of 6MP concentrations during the infusion of 6MP and 
in equimolar concentrations after stopping the infusion of 6MP. In goats 
combined steady state plasma concentrations of 6MP and 6MPR were 10 vM. 
In patients a mean 6MP concentration of 6.2 μΜ was observed during stea­
dy state by Zimm and coworkers. Moreover, these concentrations were sus­
tained during the infusion, so the prolonged exposure necessary in vitro 
to achieve an important cytotoxic effect, is simulated by these prolon­
ged infusions. 
For 6TG less data are available, however the penetration of 6TG into 
the CSF is excellent. In goats a steady state 6TG concentration of about 
3 μΜ was attained after a two-hours infusion at a dose rate of 2 mg/kg/ 
hour. However, the concentrations of 6TGR exceeded those of 6TG Itself, 
resulting in a combined 6TG/6TGR steady state concentration of 10 μΜ. 
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The prolonged infusion of 6TG at approximately 2 mg/kg/hour should be 
studied further in humans, because interspecies metabolic differences 
are an obstacle to transposing data from animals to man. 
Some important points should be taken into account, when applying high 
dose infusions of 6MP and 6TG. Both 6MP and 6TG are S-phase specific 
agents, showing a delayed cytotoxic action. The incorporation into DNA, 
for both 6MP and 6TG, as 6-thio-dGTP is a critical step in the cytotoxic 
mechanism. So it is clear that 6MP and 6TG can only exert an optimal 
cytotoxic effect on actively proliferating tumours. In human leukaemia 
this situation is most likely to be present after a haematological re-
mission is induced by other, non-phase specific, anticancer drugs. 6TG 
and 6MP given as continuous infusions are likely to have their best ap-
plication in intensive consolidation courses. The excellent penetration 
of 6TG and 6MP into CSF can be of particular value, for in leukaemia the 
central nervous system is considered to be a pharmacological sanctuary. 
In the treatment of micrometastasis, a situation in which tumour cells 
are actively proliferating, 6TG and 6MP may have some activity too. 
DeVita (1983) discussed excellently the manifold aspects of the rela-
tionship between tumour mass and chemotherapy (30) . The predominating 
problem is that in the phases of treatment as mentioned above, the 
effect of drugs cannot be determined directly, because the tumour cells 
to be destroyed are not visible and measurable. The concepts and methods 
presented eloquently by James Holland (1983) , in an important overview 
entitled: "Breaking the cure barrier", are helpful in understanding and 
measuring indirectly the effects of chemotherapy on invisible tumour 
loads (31). 
Metabolic effects of 6MP, 6TG and their metabolites may interfere with 
the cytotoxic effects. This is signalled by in vitro studies, which sho-
wed that there may exist a concentration range for an optimal cytotoxic 
effect, with decreasing cytotoxicity at increasing concentrations (32, 
33). The rule of "the higher the dose, the greater the cell kill", which 
applies to cytotoxic agents in general, may not necessarily be true for 
6MP and 6TG. 
The interaction of 6MP and 6TG with other drugs needs more investiga-
tion. Not so much the well-known interaction of 6MP and allopurinol, 
but especially interactions which could result in an enhanced incorpo-
ration of 6MP and 6TG into DNA and RNA should be considered. The intra-
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cellular PRPP concentration is critical for the first anabolic step of 
6MP and 6TG. PRPP concentrations can be increased in vitro by pyrro-
line-5-carboxylate (34), or by previous exposure of cells to methotrexa-
te (35, 36). Such an approach will complicate clinical drug therapy, but 
may increase the efficacy of 6TG and 6MP as anticancer drugs. Besides 
time-dependent metabolic and cytotoxicity increasing effects, the combi-
nation of MTX and 6MP may have advantages as fas as resistance to thio-
purines is concerned. The resistance to 6MP and 6TG is often coupled 
with an increased sensitivity to inhibitors of the purine de novo syn-
thesis (37), and MTX is one of the more potent of such inhibitors. 
Another mechanism of resistance to thiopurines, the increasing catabo-
lism of thio-nucleotides by increased alkaline phosphatase activity (38), 
can be handled by prolonged infusions which lead to continuous delivery 
of 6MP and 6TG to malignant cells. Of course, thiopurines used either 
alone or in combination with for instance MTX, are best alternated with 
other non-cross-resistant chemotherapy (39). 
In order to apply infusions of 6MP and 6TG for 24 hours and longer, in 
the treatment of leukaemias, we first should give up the concept of 
standard maintenance therapy. The limited value of maintenance treatment 
in malignant diseases, which are curable by chemotherapy, has been dis-
cussed extensively by Frei and Canellos (7). The appreciation that a 
maintenance approach is inadequate in preventing relapse in adult ALL 
patients led to the design of intensive, multidrug programs, resulting 
in remissions persisting for more than 3 years in 40% to 60% of adult 
patients (40). The essential role of curative consolidation chemotherapy 
in AML was recently discussed in a leading article in the Lancet. At the 
end of the paper the following question was asked regarding the treat-
ment of childhood ALL patients: "Might one achieve equally good or even 
better results with curative consolidation chemotherapy instead by low-
dose maintenance therapy?" (41). 
CONCLUSION 
In our opinion high-dose prolonged infusions of 6MP and 6TG deserve 
further investigation in man. In this way the in vitro optimal condi-
tions for maximal cell kill can be simulated. Although 6MP infusion has 
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received somewhat greater attention, there are arguments to included and 
even favour 6TG (Chapter VII, VIII). 
By administering 6MP and 6TG as prolonged infusions, the ability of the-
se drugs to reach the CNS may be exploited best. So 6MP and 6TG can turn 
out to be effective drugs in the prophylaxis and treatment of CNS leu-
kaemia. Besides 6TG and 6MP, their ribosides are worth considering, be-
cause 6TGR and 6MPR are more soluble than their parent drugs. Our fin-
dings in goats on the presence of 6TGR and 6MPR after administration of 
6TG and 6MP call attention to the fact that also their active metaboli-
tes should be taken into account, when considering the total biological-
ly active drug concentration. 
Anyhow, we should investigate 6MP and 6TG in a clinical setting, with-
out the prejudice of customary maintenance treatment of ALL. The fact 
that intracellular processes are ultimately responsible for the cyto-
toxic action of 6MP and 6TG should not hold us back to perform further 
pharmacological investigations. The most critical pharmacological prin-
ciple that must always be recognized in attempting to improve drug 
treatment of cancer is "an otherwise effective drug will not kill a 
drug-sensitive tumour cell that it cannot (or does not) reach in lethal 
concentration" (42). 
Ideally one should not only measure all relevant metabolites of 6MP and 
6TG in plasma, CSF and urine during pharmacological and pharmacokinetic 
studies, but also try to quantitate metabolites intracellularly, and 
preferably in the target cells. 
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SAMENVATTING 
Bij de behandeling van kinderen met leukemie neemt 6-mercaptopurine 
(6MP) een centrale plaats in. De antimetaboliet 6MP wordt al meer dan 30 
jaar gebruikt op nagenoeg dezelfde wijze, namelijk dagelijks een lage 
dosis oraal gedurende een lange periode. Na literatuurstudie bleek nog 
weinig bekend over de relatie van dosering en daaruit voortvloeiende 
concentraties van 6MP in bloed en andere lichaamsvloeistoffen. 
6MP is een analoog van de purine base hypoxanthine. Purine basen zijn 
natuurlijke stoffen die essentieel zijn voor de vorming van ribo- en 
deoxyribo-nucleïne zuren. 6MP kan worden ingebouwd in DNA en RNA en dit 
kan uiteindelijk leiden tot de dood van de (kwaadaardige) cel. 
De toepassing van 6MP binnen de behandeling van acute lymfatische leu-
kemie berust tot nu toe op empirische basis. De vraag stelt zich of en 
in hoeverre de gebruikelijke dosering en wijze van toediening zodanig 
zijn, dat een optimaal resultaat bereikt wordt met een minimale toxische 
werking. Voor 6-thioguanine (6TG), een analoog van de purine base gua-
nine, geldt dezelfde vraagstelling. 6TG wordt hoofdzakelijk toegepast 
bij de behandeling van acute myeloide leukemie. 
Binnen de afdelingen kindergeneeskunde en anthropogenetica was reeds een 
uitgebreide kennis op het gebied van de purine stofwisseling aanwezig en 
op deze basis werd het onderzoek naar de purine analogen 6MP en 6-thio-
guanine (6TG) opgezet. 
Als eerste stap in het onderzoek is het noodzakelijk de concentratie 
van 6MP en 6TG in lichaamsvloeistoffen te bepalen. Men dient te beschik-
ken over gevoelige bepalingsmethoden en omdat deze niet beschikbaar wa-
ren, werden die door ons ontwikkeld. Deze hogedruk vloeistof chromato-
grafische methoden worden beschreven in de hoofdstukken II en III. 
De minimale detectiegrens hiervan kon worden verlaagd tot 3 ng/ml • 
16 nmol/1. 
In hoofdstuk IV wordt een oriënterend onderzoek beschreven bij patiën-
ten met acute lymfatische leukemie die het protocol volgen van de SNWLK. 
Dit houdt ondermeer in dat zij een z.g. onderhoudstherapie krijgen, 
waarbij dagelijks 6MP toegediend wordt in een dosering van 50 mg/m2, met 
daarnaast eenmaal per week een dosis methotrexaat. Dit onderzoek gaf de 
navolgende resultaten. De gemiddelde concentratie van 6MP na 35 dagen 
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orale toediening is 0.064 μΜ in het plasma en 0.029 μΜ in het hersen-
vocht (liquor cerebrospinalis). Tevens wordt vastgesteld dat 6MP e'én tot 
vier weken na het stoppen van de therapie nog steeds in het plasma aan-
toonbaar is. Om nader inzicht te krijgen in deze fenomenen diende dier-
experimenteel onderzoek te geschieden. 
In hoofdstuk V wordt een onderzoek bij de hond beschreven, waarbij 6MP 
in analogie met de gebruikelijke onderhoudstherapie wordt gegeven. Na 
eenmalige orale toediening van 6MP aan de hond wordt een lage "piek" 
concentratie vastgesteld. Na intraveneuze "bolus" injektie wordt een re-
delijk hege piek concentratie gevonden, doch vier uur later is 6MP 
nauwelijks meer in plasma aantoonbaar. Het concentratietijd beloop na 
bolus injektie past bij een twee compartimenten farmacokinetisch model, 
met halfwaarde tijden van 13 tot 21 en 125 tot 151 minuten. De bereikte 
plasma concentraties zijn laag, wanneer men deze vergelijkt met die 
welke in in vitro studies worden gebruikt. Om een maximaal celdodend 
effekt te krijgen lijkt het noodzakelijk 6MP intraveneus over een lange-
re periode toe te dienen. Tevens is het van belang na te gaan hoe 6MP 
zich over het lichaam verdeelt. 
In hoofdstuk VI wordt hierop nader ingegaan. 6MP wordt per infuus toege-
diend. De verdeling van 6MP en metabolieten over het lichaam wordt door 
middel van autoradiografie bestudeerd. Het verloop van de concentratie 
van 6MP en metabolieten wordt in plasma bepaald. Hierbij blijkt dat er 
een metaboliet, namelijk 6-mercaptopurine riboside (6KPR) in het plasma 
voorkomt en dat de concentratie van deze metaboliet, vooral na het stop-
pen van de 6MP toediening, relatief hoog is t.o.v. de 6MP concentratie. 
De metaboliet, 6MPR, kan alleen gemetaboliseerd worden tot 6MP. De bio-
logisch beschikbare concentratie van 6MP kan daarom beter gezien worden 
als de som van de molaire concentraties van 6MP en 6MPR. 
In de hoofdstukken VII en VIII ligt het accent van het onderzoek op 
langdurige intraveneuze toediening. 6TG, respectievelijk 6MP, worden 
d.m.v. kontinue infusie gegeven in een bepaalde dosering per tijdseen-
heid. Voor deze experimenten is de dwerggeit het meest aangewezen proef-
dier vanwege de ervaring, die wij bij eerder onderzoek met dit model 
hadden verworven. Zo kan het aantal proefdieren tot het minimaal noodza-
kelijke beperkt worden. Bij langdurige intraveneuze toediening mag men 
verwachten dat het plasma concentratie-tijd verloop beter vergelijkbaar 
is met de concentratie en tijdsduur die in vitro nodig zijn om een maxi-
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maal celdodend effekt te bereiken. Bij deze onderzoeken op geiten waren 
we speciaal geïnteresseerd in de mate waarin 6MP en 6TG in het hersen-
vocht doordringen. 
Bij geiten blijkt de concentratie van het riboside van zowel 6TG als 
6MP de concentratie van de oorspronkelijk toegediende verbinding in 
ruime mate te overtreffen, zowel tijdens als na het stoppen van de in-
fusie. Bij geiten worden dus de biologisch beschikbare concentraties van 
6TG en 6MP in belangrijke mate mede bepaald door die van 6TGR en 6MPR. 
De penetratie van 6TG en 6MP in het hersenvocht is uitstekend. Ook de 
ribosiden dringen uitstekend door in de liquor cerebrospinalis. 
In de urine wordt het grootste gedeelte van de toegediende dosis van 
6MP, resp. 6TG terug gevonden, zowel in de vorm van de oorspronkelijke 
verbinding als in de vorm van het riboside. De concentratie van 6MP en 
6MPR, resp. 6TG en 6TGR, in de urine is globaal gelijk. 
In hoofdstuk IX geven we een overzicht over de resultaten van onze eigen 
onderzoeken en we bespreken in het kort recente onderzoeken die in de 
literatuur gepubliceerd zijn. De gebruikelijke orale toediening van 6MP 
en 6TG resulteert in nauwelijks meetbare concentraties in plasma, ter-
wijl in in vitro onderzoeken hoge concentraties gedurende een langere 
periode nodig zijn om een maximaal celdodend effekt te verkrijgen. De 
toepassing van purine analogen op klinische en empirische basis lijkt 
achterhaald. Farmakologische en metabole onderzoeken bij proefdieren en 
mensen moeten alsnog worden verricht om een wetenschappelijke basis te 
verschaffen voor de toepassing van 6MP en 6TG. 
We konkluderen dat onderzoeken, zoals door ons bij proefdieren zijn ver-
richt, voortgezet moeten worden bij de mens. Door 6TG of 6MP per lang-
durig infuus in vrij hoge dosering toe te dienen, kunnen we zorgdragen 
voor de aanwezigheid van relatief hoge concentraties van 6MP of 6TG in 
het bloed gedurende een lange periode. Tevens scheppen we dan de beste 
voorwaarden waaronder 6MP en 6TG in de hersenen en in het hersenvocht 
kunnen doordringen. Dit zou er toe kunnen leiden dat 6MP en 6TG een 
andere rol in de behandeling van kwaadaardige aandoeningen kunnen gaan 
spelen. Te denken valt aan de zogenaamde profylaxe en de behandeling van 
leukemie in het centraal zenuwstelsel en de behandeling van hersentumo-
ren. 
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Het schrijven van een proefschrift mag soms lijken op een eenzame reis 
door nog niet in kaart gebrachte gebieden; de steun van velen bij de 
voorbereidingen en de reis zelf is onontbeerlijk. Allereerst wil ik die-
genen danken die niet met name genoemd worden of omdat de regels dit 
verbieden of omdat mijn geheugen te kort schiet. Onder de eerste kate-
gorie vallen mijn promotor en de co-auteurs bij de artikelen. De aktieve 
bijdrage aan de voltooiing van het proefschrift die de promotor ondanks 
of juist dankzij zijn emeritaat heeft geleverd, zal ik mij dankbaar 
blijven herinneren. De tweede kategorie is niet nader te duiden. 
Mijn analisten, John van Baal en Marinella van Leeuwen, dank ik voor de 
essentiële rol die zij speelden in de ontwikkeling van de bepalingsme-
thoden en de uitvoering van bepalingen en dierexperimenten. John dank 
ik speciaal voor het in kaart brengen van de gegevens. De schema's en 
grafieken in het proefschrift werden door hem vervaardigd en samen met 
hem werden de illustraties in het manuscript verwerkt. 
Bij de voorbereiding en uitvoering van de dierexperimenten was de hulp 
van vele medewerkers van het Centraal Dierenlaboratorium (hoofd Dr.W. 
J.I. van der Gulden) onmisbaar; speciaal Theo Arts, Gerrie Grutters en 
Albert Peters wil ik daarvoor danken. 
De medewerking van de afdeling Medische Fotografie (hoofd A.T.A. Reij-
nen) bij het verwerken van de vele illustraties was lofwaardig. 
De medewerking van de medische bibliotheek, onder de deskundige leiding 
van het hoofd E.de Graaff, evenzo. 
Het leesbaar maken van de handgeschreven versies van het manuscript is 
de verdienste van Loes Viering. De latere versies van de artikelen en 
hoofdstukken werden verzorgd door Janny Palthe en Kitty van den Tempel. 
Loes, Janny en Kitty excuses voor het drammen dat ik deed, en mijn gro-
te dank; vooral Kitty die de vele "allerlaatste" versies en het druk-
klaar maken van het manuscript verzorgde. 
Behalve de vele co-auteurs heeft met name Dr.J.A.J.M.Bakkeren steeds ge-
waakt over een respectvol gebruik van de Engelse taal; als ik daarin ge-
slaagd ben is dat voor een groot deel zijn verdienste. 
Mijn gezinsleden, Ineke, Lyke en Токе, zijn vaak "lijdende" personen ge­
weest, niet alleen door de spanning die promoveren met zich meebrengt, 
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maar ook door andere faktoren, die ik hier niet verder wil benoemen. 
Het gedicht van Токе verwoordt deze spanningen beter dan ik dit kan. 
Mij leidt dit en de atronding van het proefschrift tot pogingen om in­
houd te geven aan de volgende regel uit het lied "enkel en alleen" (R. 
Chrispijn, Herman van Veen): "Langzaam begin ik te begrijpen waar het 
allemaal om draait". 
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STELLINGEN 
Behorende bij het proefschrift 
6-MERCAPTOPURINE AND 6-THIOGUANINE: 
A FRESH LOOK ON VINTAGE ANTICANCER DRUGS 
In het openbaar te verdedigen 
op donderdag 23 mei 1985 
des namiddags te 4.00 uur 
door 
TEUNIS JAN SCHOUTEN 
I 
De tot nu toe gebruikelijke toepassing van 6-mercaptopurine en 
6-thioguanine, uitsluitend gebaseerd op empirisch-klinische ervaring, 
is achterhaald. 
II 
De voorspelbare en o.a. in dit proefschrift aangetoonde goede pene-
tratie van 6-mercaptopurine en 6-thioguanine in de liquor cerebro-
spinalis is bij de mens, met name wat betreft de therapeutische effec-
ten, onvoldoende onderzocht. 
III 
De toediening van 6-mercaptopurine en 6-thioguanine per langdurig 
infuus dient bij de mens nader onderzocht te worden. 
IV 
Het in vitro aangetoonde metabole synergisme van methotrexaat en 
6-mercaptopurine lijkt ook bij patiënten te kunnen worden benut. 
(J P.M. Bòkkerink, T J . Schouten, R.A. De Abreu, et al. Tijd Kindergenccsk 
1984;52:118-123, J.P.M. Bökkeiink, persoonlijke mededeling) 
V 
Onderhoudstherapie bij een curatief te behandelen maligniteit is 
onjuist. 
(E. Frei III and G.P. Candios, Am J Med 1980; 69:585-594) 
VI 
De kans op ziektevrije overleving van acute lymfatische leukemie is 
afhankelijk van de initiële therapie. 
VII 
Restverschijnselen van neurologische, endocriene en psychologische 
aard, bij een kind dat optimaal behandeld is voor een hersentumor, 
vereisen een "innige" multidisciplinaire samenwerking en aanpak. 
VIII 
Bij maligne histiocytose hoort, indien enigszins mogelijk, chromo-
somaal onderzoek te worden verricht. 
(T.J. Schouten, T.W.J. Hustinx, J.M.J.C. Scheres, et al. Cancer 1983;52:1229-1236) 
IX 
Interferon is van grote betekenis voor patiënten met ernstige vormen 
van juveniele papillomatosis van de larynx. 
(T.J. Schouten, W Weimar, J H Bos, et al Laryngoscope 1982, 92 686-688) 
X 
Bij het ernstig benauwde stridoreuze kind hoort d.m.v. een "dwarse 
hals" röntgenopname een epiglottitis te worden aangetoond c.q. uit-
gesloten. 
XI 
Voor het vaststellen van het tijdstip van starten van C.A.P.D. (continue 
ambulante peritoneaal dialyse) bij het jonge kind is te weinig rekening 
gehouden met de mogelijkheid van progressieve hersenbeschadiging 
bij conservatieve behandeling. 
(A. Rotundo, TX Nevins, M. Lipton, et al Kidney Int 1982, 21 486^91) 
XII 
De optimale concentratie van koper, ijzer en zink van de geadapteerde 
zuigelingenvoeding is niet eenvoudig af te leiden uit de concentraties 
van deze stoffen in moedermelk. 
(R M Feelcy, R R Litenmillei, J В Jones, et al. Am J Clin Nutrition 
1983,37 443-448) 
XIII 
Als wetenschappelijke medewerkers worden geacht te publiceren en 
te promoveren, dan dient de administratieve formatie van een afdeling 
hierop afgestemd te zijn. 
XIV 
Ook voor het gezin van de promovendus is promoveren een kwestie 
van afzien. 
XV 
In overdrachtelijke zin is het op sloffen promoveren plezierig, maar 
tijdens het schrijven van het proefschrift zijn klompen boven sloffen 
te verkiezen 
Nijmegen, 23 mei 1985 Teunis J. Schouten 



